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FOR VASCULAR AND CARDIAC RECONSTRUCTION 
Allison M. Ostdiek 
Dr. Sheila Grant, Dissertation Supervisor 
 
ABSTRACT 
 It is a universally acknowledged truth that biomaterials are an essential 
part of current medical therapies.  Biomaterials comprised of decellularized tissue 
mimic natural tissue by providing a natural extracellular matrix.  Gold 
nanoparticles have been shown to improve wound healing by decreasing free 
radicals at the site and hinder collagenase binding sites, thus improving the 
durability of the material.  This dissertation examines decellularized porcine 
arterial tissue conjugated with gold nanoparticles for use as a vascular and 
cardiac repair.  The material was characterized through numerous in vitro tests, 
including biocompatibility assays, cell proliferation assays, mechanical testing, 
histology, and scanning electron microscopy.  It was further investigated through 
two in vivo studies allowing for closer examination of the body’s interaction with 
the material.    The results of these tests show a material that is comparable to 
natural tissue with regard to biocompatibility and mechanical strength.  The 
material is feasible in a vascular environment and shows better in vivo 
biocompatibility and superior cell reintegration when compared with current 
biomaterials used in vascular repair.  Further studies are needed to evaluate the 
xiii 
 
patch in a diseased environment to better understand the role of the gold 
nanoparticles.  This material has the potential to create a new class of 
biomaterials for use in cardiovascular work.   
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Chapter One 
LITERATURE REVIEW 
 
1.1 Challenges Facing Cardiovascular Biomaterials 
Cardiovascular diseases are a major cause of morbidity and mortality in 
Western civilization [1-3].  Cardiac and vascular repair materials are used to treat 
problems such as trauma, aneurysms, congenital heart defects, and blood vessel 
wall defects [4-7].  The current variety of materials being used has a litany of 
problems, and there is a need to find an optimal biomaterial that can be used for 
these repairs through better understanding of the relationship between blood 
components and biomaterials.   
 
1.1.1 The Blood Vessel 
1.1.1.1 Normal Vascular Structure 
 In order to understand the process of vascular repair we must first 
understand the basic structure of a normal artery.  There are three layers in the 
large and medium arteries, consisting of the intima, media, and adventia.  These 
layers are present in the smaller vessels as well, but less defined.  The innermost 
layer, or intima, has a lining of endothelial cells attached to connective tissue.  
These endothelial cells are the layer that contacts the blood [2].  The importance 
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of the endothelial cell layer cannot be overstated, as endothelial cells have been 
noted to be more than a passive barrier cell, but rather a cell that can both create 
and distribute copious important compounds that effect numerous bodily 
reactions.  Furchgott and Zadwaski first observed that the endothelial cell played 
a much more active role than previously considered, and from there the 
realization of the importance of the endothelial cell has grown exponentially. The 
work they began expanded to show that the endothelial cell synthesizes 
compounds that include molecules such as growth factors, vasoactive factors, 
coagulation and platelet adherence modulators, and chemotactic factors.  The 
cells mediate vasodilation, vasoconstriction, and overall help maintain 
homeostasis of the extracellular matrix within the vessel wall [8-13].   
The media, or middle layer, is a concentric organization of smooth muscle 
cells (SMCs) and bands of elastic tissue.  The luminal endothelial cells affect the 
SMCs through the release of mitogens such as epidermal growth factor and 
platelet derived growth factor and also cause relaxation of the smooth muscle 
cells via acetylcholine [8, 14, 15].   In 1979 Chamley-Campbell et al. showed that 
the smooth muscle cells have two main phenotypes which represent SMCs that 
contract and SMCs that synthesize extracellular matrix (ECM), with overlap of the 
two phenotypes in individual cells [16].  These SMCs lie in an interstitial matrix 
that also contains type 1 and type 3 collagen with fibronectin and chondroitin 
sulfate.  Also present are lamellae containing large amounts of elastin [17].  
SMCs play an important role in the formation of ECM during both angiogenesis 
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and vascular healing.  The media heavily influences blood pressure and vascular 
resistance.  Changes in the smooth muscle layer can lead to vascular stenosis, 
hypertension, ischemia, and vasospasm [8].   
The outer layer is the adventitia which is made up of a collagenous 
extracellular matrix that has fibroblasts and other cells, and adds rigidity to the 
vessel.  It surrounds the tunica media and plays a critical role in the overall 
homeostasis of the vessel.  The adventitia is the interface between the body, the 
media, and the intima and contains important immune cells such as T-cells, B-
cells, and mast cells while also containing lymphatic vessels and autonomic 
nerves [18-22].  The presence of these indicates that the adventitia helps to 
regulate the vessel’s lumen size by controlling medial smooth muscle tone and 
wall remodeling responses, including the formation of microvessels that feed the 
inner vessel layers [18, 23].  All three vascular layers depend upon one another 
to create a healthy working vascular environment.   
 
1.1.1.2 Vascular Repair 
The manner in which vascular tissue repairs itself is a major hurdle in the 
design of successful biomaterials.  Vessels have a delicate homeostasis.  
Thromboembolism formation and subsequent vessel narrowing and occlusion 
are the more immediate troublesome healing responses to vessel injury. The 
initial response to injury is platelet deposition and the initiation of the coagulation 
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cascade.  This response begins when the endothelium of the vessel is 
interrupted either through loss of cells or the addition of foreign materials.  The 
exposure of the collagen due to the injury of the endothelial cells leads to the 
exposure of collagen fibrils which in turn begins the process of primary 
hemostasis - platelet adhesion and thrombus formation through activation of the 
intrinsic pathway - and the secretion of agonists such as adenosine phosphate, 
serotonin, and thromboxane [24, 25].  As the cascade continues, more platelets 
are activated, and adhere to the vessel wall in layers, eventually leading to the 
formation of thrombin and the beginning of secondary hemostasis.  Secondary 
hemostasis leaves a platelet plug within the vessel at the site of the initial 
damage [26].  The thrombus decreases the cross sectional area available for the 
blood to flow through, in turn causing yet more platelet interactions with the 
vessel walls and the formation of larger clots.  Eventually these clots can occlude 
the entire vessel or break off to cause ischemic attacks elsewhere in the body.  
These can clots occur with both injuries to the vessel and when the blood comes 
into contact with a foreign object, such as an implanted biomaterial.   
Thromboembolisms and vessel occlusions are immediate problems with 
vascular injury and healing.  The longer term consequence is an overzealous 
wound healing response known as intimal hyperplasia.  Intimal hyperplasia is the 
term for intimal thickening caused by increased amounts of cells and ECM in the 
vessel caused by injury, inflammation, and increased wall stress [17, 27].  There 
are numerous compounding mechanisms that create intimal hyperplasia, though 
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some of the causes of cell signaling changes leading to stimulation of 
proliferation are yet unknown [28].  Intimal hyperplasia begins with platelet 
deposition and coagulation, followed by increased SMC migration and 
proliferation and an increase in the laying down of ECM.  The initial mechanisms 
begin with the changes in the normal endothelial mechanisms.  Alterations in 
endothelial derived substances likely result in a decreased ability to regulate 
coagulation and an increase in SMC activity [29].  The SMCs of adult arteries 
rarely need to proliferate, but are able to quickly divide in response to vascular 
injury [30].   As previously discussed, vascular SMCs have two main phenotypes: 
those that contract and those that synthesize ECM.  In normal vessels the 
synthesis of the extracellular matrix is balanced by continuous degradation.  
However in injury more SMCs are needed to divide and regenerate, and there is 
a change in the active genes which leads to basement membrane components 
such as laminin to be down regulated while increasing interstitial matrix 
components like type 1 collagen, elastin, and fibronectin [17, 31-33].  Over time 
the synthesis of excessive ECM results in a hyperplasia, a decreased vessel 
lumen, and stenosis of the vessel.   
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1.1.2 Blood – Material Interactions 
1.1.2.1 Material Surface Interaction  
 Vascular repair materials present unique challenges due to the highly 
variable environment into which they are implanted.  Vascular biomaterials are in 
constant contact with blood which requires them to have particular characteristics 
in order to be biocompatible.  When placed in a vessel they trigger the intrinsic 
pathway causing coagulation and the inflammatory stage of the wound healing 
response.  The differences in coagulation reactions to native endothelial and 
artificial surfaces have been studied for over 100 years [34].  The objective of 
examining the blood-biomaterial interaction is to understand the effects the 
biomaterial has on the components of the blood and the subsequent 
thrombogenicity of the material, or how it induces the coagulation response [35].  
The blood response is affected by the texture, composition, and charge of the 
graft surface as well as the structure and chemical composition of the entire graft 
[36].    A reaction to the material can cause a wide variety of problems, including 
thrombi partially or totally blocking blood vessels, and the formation of emboli 
that can cause strokes [37].  The surface chemistry of the material must promote 
cell attachment, proliferation, and migration to allow for ingrowth of host cells 
through a predictable interaction while also being biocompatible [38, 39].   
 A foreign material implanted into the body is not thromboresistant like the 
native endothelium and cannot secrete factors to actively aid in 
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thromboresistance [35, 40, 41].  The initial contact of blood to the biomaterial 
triggers the adsorption of proteins such as fibrinogen, albumin, and factor XII to 
the surface which in turn promote the adhesion and aggregation of platelets [34].  
Many of the consequences seen after this are due to the interactions of the blood 
with the adsorbed protein layer [35, 42].  The immune response includes the 
initiation of the extrinsic and intrinsic coagulation cascades and formation of 
thromboemboli as previously described.  The body also responds as it would to 
any foreign material with an inflammatory response including neutrophils, 
macrophages, and multi-nucleated giant cells [43].  As these cells attack the 
material they attempt to ingest it, and when they cannot, the body sometimes 
walls off the material.  This can lead to chronic inflammation and other implant 
issues.    
 Another major aspect to the blood-material interaction is the flow 
mechanics within the vessel.  Different types of vascular materials have different 
levels of compliance.  A more compliant graft may match mechanical and flow 
parameters better than a less compliant material [44].  Changes in the flow of the 
blood lead to some of the problems previously described and contribute yet more 
challenges to a blood contacting biomaterial such as atherosclerosis and 
vascular plaques [45].  Normal blood plasma behaves like a Newtonian fluid, 
flowing through the arteries in a pulsatile fashion, and thus the force applied to 
the fluid is related to the velocity gradient within the fluid with consideration to the 
viscosity [46].  When the flow through the vessel is altered due to injury or repair 
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with a biomaterial the stress placed on the wall of the adjacent artery is changed.  
Over time the body adapts to these changes by remodeling the artery.  Increased 
flow rates will cause a larger diameter vessel with the same arterial structure 
while decreased flow will see a thickening of the intimal layer [47].  Changes to 
the medial layer include the proliferation of SMCs and changes in the 
organization of the elastin and collagen structure.  Long term hypertension 
caused by changes in the size of the vessel, including vascular wall repair, lead 
to a generalized thickening of the media [47, 48].    
Variation in flow and thus shear stress on the artery can lead to intimal 
hyperplasia and has been seen when using vascular grafts of differing diameters 
[49].  With vascular biomaterials we can see thrombosis and intimal hyperplasia 
leading to stenosis.  When stenosis occurs the shear stress on the walls of the 
arteries changes with intense turbulence downstream of the stenosis and can 
lead to further platelet adhesions and thrombi [50].  In addition to all of the 
physiological responses there is added stress to the biomaterial that can lead to 
weakening and early failure of the implant.  The consequences of altering the 
vascular flow emphasize the need for vascular biomaterials that can mimic the 
native tissue.   
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1.2 Current Materials for Cardiovascular Repair 
Cardiac and vascular materials are utilized to treat trauma and 
aneurysms, repair congenital defects, and patch defects in vessel and cardiac 
walls [4-7].  Materials used currently for vascular and cardiac repairs tend to fall 
into two categories: Those created from synthetic materials and those with a 
biologic origin.  Both have strengths and weaknesses.  Surface modifications to 
both synthetic and biologic materials are also being explored as a way to 
enhance biocompatibility.  There are numerous characteristics for an ideal 
vascular graft, all of which entail making the graft as close to a native vessel as 
possible.  The first set of requirements are those of any implant: biocompatibility, 
easy sterilization, stable and convenient to store for long periods of time, and 
ease if implantation.  The more specific requirements for a vascular graft include 
having the same composition, structural, and mechanical properties.  It should 
mimic the native extracellular matrix, sustain and guide new cell growth, avoid 
intimal hyperplasia, resist infection, and degrade after new tissue has formed [1-
3, 44, 51, 52].   
 
1.2.1 Synthetic Repair Materials 
 Vascular materials have been created from synthetic polymers, such as 
expanded polytetrafluoroethylene (ePTFE), and polyethylene terephthalate 
(PET).  These synthetic polymers provide excellent mechanical strength and in 
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vivo durability, but lack biocompatibility leading to intimal hyperplasia, thrombus 
formation, calcium deposition, and increased rates of infection [7, 53-63]. 
 Synthetic polymers cause an immune reaction in the body that can be 
extremely problematic when they come into contact with blood.  Normally when a 
synthetic material is implanted the immune response sends phagocytic cells to 
the area to try and remove the foreign material.  This creates an inflammatory 
response that becomes chronic as the material remains in the body for years.  
Biomaterial surface activated coagulation occurs more frequently with synthetic 
materials.  They completely lack any biomolecules such as those created by 
endothelial cells.  As previously discussed, this absence causes high levels of 
platelet adhesion and the downstream consequences.  A material’s 
thrombogenicity can result in failure and major in vivo complications such as 
pseudoaneurysm formation [37, 64-66].  
 The synthetics lack a “natural” extracellular matrix (ECM) and 
subsequently lack the molecules and growth factors present in biologic tissue 
that signal the body to start re-integrating cells into the matrix.  They can induce 
a low level of inflammation due to a foreign body response that will result in late 
graft failure [36].   They have higher infection rates than biologic materials and 
show a greater tendency towards forming biofilms.  These infections can later 
lead to increased material removal and mortality rates [67, 68].  Overall, synthetic 
materials lead to numerous unappealing reactions within the native tissue.   
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1.2.2 Biologic Repair Materials 
 Current cardiovascular biologic patch materials include autologous and 
cadaver vessels and natural extracellular matrices from animals.  Biologic 
materials allow for the host cells to infiltrate the implant and remodel it into a 
functional living tissue [69, 70].  These materials better approximate 
characteristics of the native tissue than synthetic materials, and can be 
engineered to include the host’s own cells.  However, since they are organic they 
tend to be weaker than the synthetic materials, and break down faster within the 
body.  Certain types can also cause immune reactions if they are not treated 
correctly.  Biologic materials tend to fall into three categories: autologous grafts, 
tissue engineered grafts, and decellularized xenografts, with some overlap.   
 In humans the gold standard for most vascular repair situations is the 
autologous graft.  When a person’s own tissue is used to graft a vessel there is 
little chance of immune rejection.  However, in many cases patients do not have 
viable tissue available for use, and resulting in a secondary surgical site.  In 
particular, when veins are used to replace arteries the grafts do not always 
thicken to the strength of arteries and can develop stenosis or failure later on.  
Cadaver tissues have also been cryopreserved and implanted into patients with 
the hopes that the endothelial cells of the allograft would remain viable and help 
improve patency [71].  However Sachs et al. showed that frozen cryopreserved 
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veins lose endothelium and fibrolytic activity five days after grafting [72].  The 
traditional allografts express major histocompatibility complex antigens I and II, 
which lead to immune reactions and thrombosis in these grafts [73].  Cadaver 
tissue is also of limited availability and can transmit diseases [74].   
 One of the most popular areas of biologic materials research is the use of 
a natural extracellular matrix (ECM) as a base material for scaffolding.  This 
process has been used with multiple tissues, including small intestine 
submucosa [75, 76], heart valves [77-80], blood vessels [81-83], urinary bladder 
[84], bovine pericardium, and many others [85].  ECM tissues serve as scaffolds 
for cell attachment, migration, and proliferation.  They provide the added benefits 
of having growth factors and RGD-peptides present, as well as other unknown 
factors that seem to aid in the repopulation and revascularization processes [86].  
Xenografts closely mimic the host tissue’s original mechanical and structural 
properties and have a lower infection rate [87].  The structural and functional 
molecules differ in each tissue and organ.  Therefore, different organ and tissue 
ECMs vary in structure and in biomolecules [85].  
The bioactive factors remain behind after decellularization, which is a 
process necessary to remove the immunogenic components present.  The 
decellularization process is vital to the creation of ECM grafts.  The goal is to 
remove all cellular components while leaving the ECM and cell associated 
proteins, such as actin, tubulin, and myosin [88, 89].  There are several methods 
of decellularization being explored which include ionic and non-ionic detergents 
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and enzymes.  The ionic detergents, such as sodium dodecyl sulfate, remove 
nuclear remnants, but may disrupt the native tissue structure and cause a 
decrease in glycosaminoglycans.  Non-ionic detergents, such as Triton X-100 
also remove nuclear remnants, but have had mixed reports of decreasing the 
tensile strength of the scaffold [90, 91].  Zwitterionic detergents have been shown 
to improve the efficacy of the non-ionic detergents without causing further 
damage to the ECM.  Enzymatic treatments cleave the nuclear remnants, but 
can be hard to remove from the tissue and cause an immune response [92].  A 
protocol that removes the nuclear remnants and does not disrupt the ECM is the 
ideal basis for a vascular graft.   
Another method of modifying ECM to optimize a biomaterial is 
crosslinking.   Crosslinking was originally used to decrease the resorption rate of 
the material in vivo [87].  Crosslinking can be done to strengthen the scaffold as 
well as create larger pore sizes for cells to grow into.  Crosslinking collagen 
molecules has been shown to promote resistance to protease degradation [93].   
This increases the in vivo durability of the material.  Traditionally, glutaraldehyde 
has been used as a crosslinker with natural tissue.  However it is cytotoxic at 
high levels and is a bridge forming crosslinker.  Other chemical crosslinkers 
include disocyanates, acylazide, and 1-ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide (EDC).  EDC is a zero-length crosslinker that directly links the 
collagen molecules to one another.  Some studies have shown EDC crosslinking 
creates a more biologically stable scaffold [94, 95].  Using crosslinking to create 
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a larger pore size can allow cells to colonize the scaffold.  In some ECMs the 
collagen fibers are woven too tightly for the natural cells to grow into.  With a 
larger pore size the cells and nutrients can spread into the scaffold [96].   
Crosslinking is a promising way to optimize biologic tissues.   
 
1.2.3 Surface Modifications 
 Surface modifications to biologic and synthetic materials can increase 
blood compatibility [97].  Proteins rapidly adsorb onto biomaterial surfaces when 
they are implanted.  Subsequent interactions with host fluids and tissues are 
mostly determined by this attached protein layer [35, 42].  Various methods of 
controlling the amount and types of blood components being adsorbed onto 
biomaterial surfaces are being explored.  Surface modifications that elute 
particular bioactive molecules such as heparin have shown promise in controlling 
the body’s response to the repair material.  In one study, Zhou et al. added 
vascular endothelial growth factor (VEGF) and heparin to a decellularized 
scaffold to encourage endothelial cell ingrowth and decrease coagulation.  VEGF 
is a chemoattractant for endothelial cells and also helps inhibit intimal 
hyperplasia.  The heparin helps maintain graft patency.  The study showed a 
higher cell proliferation rate and a smaller hyperplastic intimal area with the 
added VEGF and heparin [98].  Another type of surface modification that can 
improve biocompatibility is the use of nanoparticles.  
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1.3 Nanoparticles 
 Nanoparticles have a broad array of biomedical applications, such as 
imaging, drug delivery, and diagnostics [99-101].  Protein interactions occur 
within the body on a nanoscale and control numerous important cell functions 
such as cellular proliferation, migration, and ECM production, all of which have 
significant effects on the success and failure of biomaterials [102, 103].  By 
capitalizing on these effects, we can generate vastly improved nanocomposite 
biomaterials.   
 
1.3.1 Uses in Biomaterials 
 Recent research delves into cellular responses to nanomaterials present 
on biomaterials [104].  Nanoparticles have many biomaterial applications, since 
they are the size of some of the proteins essential for cellular functions and 
signaling.  Biomolecules interact with a biomaterial surface based on its surface 
chemical composition.  This protein surface interaction is part of what makes 
nanoparticles so appealing: they can directly influence these proteins.  Another 
important aspect to the surface – material interaction is the adsorption of proteins 
to the surface of the material.  Nanoparticles can improve cellular function as 
they have been shown to create a more hydrophilic material and maintain more 
crystal grains and atoms on the surface of the material.  The larger number of 
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grains contributes to protein adsorption and unfolding by increasing surface 
roughness, area, and energy [102, 105].   By affecting these interactions they 
can change the body’s reaction to the implantation of a foreign material and 
influence cellular signaling cascades [106, 107].  An excellent example of this is 
the use of silver nanoparticles as antimicrobial coatings [108].  Gold 
nanoparticles are one of many being investigated for their effects in vivo.   
 
1.3.2 Gold Nanoparticles 
  Gold nanoparticles (AuNPs) are being used in numerous medical 
applications such as drug delivery, imaging, biosensors, diagnostics, gene 
therapy, and nanocomposite biomaterials due to their biocompatibility, optical 
properties, and conjugation capabilities [100, 101, 104, 109-111].  Gold is a noble 
metal that is biologically inert.  AuNPs have been used for the immobilization of 
proteins, enzymes, and antibodies [112].  These multiple positive effects of 
AuNPs arise from the protein – gold interactions that effect cell signaling.  Recent 
research has shown that AuNPs can augment antimicrobial properties of 
biomaterials as well as increase cell proliferation [112-116].  Hsu et al. showed 
significantly lower bacterial adhesion to materials with AuNPs attached [114].  
This indicates that the presence of AuNPs on a material may prevent the 
formation of biofilms while also encouraging the body to heal and remodel 
properly. Other studies have also corroborated the bacteriostatic properties of 
17 
 
AuNPs, a major benefit for biomaterials [115].  Studies show that materials 
conjugated with AuNPs have improved cell adhesion, protein adsorption, thermal 
and mechanical properties while showing reduced foreign body reaction, 
monoctye activation, inflammatory response, and bacterial adhesion when 
compared to the same material without AuNPs [117, 118].  Using human gingival 
fibroblasts, Hsu et al. showed the addition of AuNPs to polyurethane increased 
cellular proliferation and attachment [112].  Another benefit to AuNPs is their 
ability to increase the stability of biomaterials by slowing their degradation in vivo.  
Grant et al. showed that AuNPs hinder collagenase binding sites [119].  This 
hindrance slows the enzymes the body sends to break down the foreign material, 
which allows time for proper remodeling.  Several studies have shown that 
AuNPs conjugated with biomaterials have significantly improved thermal and 
mechanical properties and improved biostability [112, 117, 120, 121]. With this 
increased stability, biomaterials conjugated with AuNPs will be able to provide a 
stronger basis for tissue reconstruction while also being more biocompatible to 
the host.  AuNPs are a strong candidate for future nanocomposite materials.   
The biocompatibility of gold nanoparticles has been highly debated.  The 
current literature shows AuNPs to be biocompatible and non-cytotoxic in vitro 
and in vivo while suggesting that cellular response is dependent on numerous 
factors such as nanoparticles concentration, size, and synthesis, and the cell line 
used in culture [122].  Current research trends show that the cytotoxicity of the 
AuNPs depends greatly on the size used and may be due to variability in uptake 
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kinetics between smaller and larger particles, concluding that smaller particles 
have more negative effects [110].  Conner et al., and Shukla et al. found in 2005 
that AuNPs larger than 18 nm show little cytotoxicity, even if they are up taken 
into a cell [123-125].  The concentration of the gold nanoparticles has also been 
a concern, but conjugated 20 nm AuNP concentrations up to 5mM have shown 
no adverse effects on mice fibroblast cells [113, 116].  Overall, gold nanoparticles 
are biocompatible and have positive effects when used in a biomedical setting.   
 
1.4 Conclusions 
 There is a unique set of challenges facing cardiac and vascular 
bioengineered materials in vivo.  Current research shows that we have numerous 
materials with varying negative and positive characteristics.  The positive 
characteristics from the materials need to be taken under consideration and 
combined into a material that is ideally suited to interface with blood.  More 
research is needed to create, characterize, and optimize a composite material 
using currently available methods that will be strong, durable, antithrombogenic, 
biocompatible, and mechanically similar to the native tissue.   
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Chapter Two 
INTRODUCTION TO RESEARCH 
 
2.1 Significance of Research 
 Cardiac and vascular materials are used to treat trauma and aneurysms, 
repair congenital defects, and patch defects in vessel and cardiac walls [1-4]. 
Finding a suitable material for these repairs included research in both biologic 
and synthetic materials, yet failed to yield a material that mimics the mechanics 
and biocompatibility of the natural tissue while not causing host complications.  
Current synthetic and biologic scaffolds can cause negative host reactions such 
as inflammation, calcification, and infection [5-10].  The significance of this 
research was to create, characterize, and optimize an improved gold 
nanomaterial tissue patch for vascular and cardiac repairs.  The material is 
created from porcine vascular tissue and conjugated with gold nanoparticles to 
improve biocompatibility, mechanical properties, cellular integration, while 
resisting calcification, intimal hyperplasia, and thromboembolism formation.     
 
2.2 Research Objectives 
 The overarching objective of this research was to characterize and 
optimize decellularized porcine arterial tissue as a vascular and cardiac repair 
material.  The initial stage was in vitro testing of the material, which examined the 
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basic characteristics and biocompatibility of the material.  The second stage 
consisted of two in vivo studies.  The first investigated several different versions 
of the experimental material to understand how it behaved in vivo and to 
compare it to a currently used material.  The second study was a long-term study 
that investigated the material in a high pressure setting to better understand the 
material’s strengths and the host’s long-term reaction to its presence.   
 The purpose of the initial in vitro work was to provide basic information 
about the mechanical strength and biocompatibility of the material, and to 
compare different surface modifications.  Published decellularization protocols 
were used to create a material composed of a non-immunogenic extracellular 
matrix (ECM) that would retain the characteristics of the native tissue.  There are 
numerous surface modifications being researched to create more favorable 
surface-blood interactions and to improve biocompatibility.  Gold nanoparticles 
have been shown in vitro to enhance cellular proliferation, reduce bacterial 
adhesion, and reduce reactive oxygen species, and were an obvious choice to 
help optimize the material [11-14].  The various modifications were examined via 
light microscopy and scanning electron microscopy (SEM) to determine if all the 
nuclear remnants were being cleared during the decellularization process, and to 
ensure the ECM was not being maimed during decellularization and crosslinking.  
The SEM also determined that the nanoparticles were still conjugated to the 
material after sterilization.  Two different biocompatibilty studies were performed 
with two cell lines to determine if any of the processing or the presence of the 
gold nanoparticles would cause changes in cell proliferation or result in 
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cytotoxicty.  Finally, mechanical studies determined the material’s strength when 
compared to the native tissue.   
 The results from the in vitro work led to two in vivo studies with swine.  In 
the first study, several differently modified patches were placed on one carotid 
artery with a commercially available material on the contralateral artery in each 
animal.  This study allowed for comparison between the various patch 
modifications, as well as between the experimental and commercial materials.  
The study also offered two time points in order to study the long and short-term 
healing responses to the material.  The second study placed the experimental 
material conjugated with gold nanoparticles over an artificially created defect in 
the thoracic aorta.  The objective of this study was to see how the material 
performed in a high pressure environment in the long-term.  The study lasted six 
months; enough time to determine if any common adverse effects such an intimal 
hyperplasia would arise.   
 The results of these experiments showed that we have created a 
nanocomposite material with numerous advantageous qualities.  Our material 
retains its natural structure through processing, shows excellent biocompatibility 
in cell culture assays, and has mechanical strength equivalent to the native 
tissue while retaining its natural structure.  The in vivo work shows that the 
material is feasible in a vascular environment and has a favorable interface with 
blood.  These studies showed that the material allows for excellent cellular 
infiltration and resists neo-intimal hyperplasia and calcification.  Overall, this 
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research proves the creation of a novel nanocomposite material tailored to a 
vascular and cardiac environment.   
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Chapter Three  
PRELIMINARY CHARACTERIZATION STUDIES 
3.1 Introduction 
 The development of a novel biomaterial requires many preliminary 
characterization studies, some of which are extremely basic steps that must be 
undertaken to ensure the biomaterial is worth further pursuit.  This chapter 
contains experiments that were not necessary for publication, but useful initial 
studies.  There are several ways we created and tested biocompatibility in our 
biomaterial.  In order to create a biocompatible material all of the native cells 
must be removed from the tissue through decellularization.  This process will 
decrease the immune response when implanted in the host and is particularly 
important with xenograft materials [1, 2].  Crosslinking is another aspect of 
creating a strong biomaterial and can improve the stability of the biomaterial by 
forming covalent bonds between the collagen fibers.  As discussed in Chapter 
1.3.2, the use of AuNPs may augment antimicrobial properties of biomaterials as 
well as increase cell proliferation [3-7].  The broad hypothesis for the experiments 
done here was that the use of crosslinking and the addition of AuNPs would not 
hinder murine fibroblast growth.  The secondary hypothesis was to test the 
biocompatibility of bovine carotid artery and compare the mechanical properties 
of bovine and porcine tissue.  These initial studies were to determine the best 
animal to harvest tissue from looking at porcine and bovine tissue and to ensure 
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that the material was biocompatible at a very basic level through the use of a 
very common cell line.    
 
3.2 Materials and Methods 
3.2.1 Chemicals 
Unconjugated gold nanoparticles (20 nm and 100nm diameter were 
purchased from Ted Pella, Inc. (Redding, CA)  The following chemicals were 
purchased from Sigma Aldrich (St. Louis, MO): ethylenediaminetetraacetic acid 
(EDTA), tributyl phosphate, 2-mercaptoethylamine, phosphate buffered saline 
(PBS), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), N,N-
dimethylformamide (DMF), 2-(N-Morpholino)ethanesulfonic acid hydrate (MES), 
TritonTM X-100 (4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol, t-
Octylphenoxypolyethoxyethanol, Polyethylene glycol tert-octylphenyl ether), 
peracetic acid, trypan blue stain, papaya latex, and L-cysteine hydrochloride. 
Acetone and sodium chloride (NaCl) were purchased from Acros Organics USA 
(Morris Plains, NJ). ATCC-formulated Eagle’s Minimum Essential Medium 
(EMEM), horse serum, penicillin-streptomycin solution, and Dulbecco’s 
Phosphate Buffered Saline (DPBS) were obtained from American Type Culture 
Collection (ATCC) (Manassas, VA). Disodium ethylenediaminetetraacetate 
(Na2EDTA) and 1X TE buffer were purchased from Fisher Scientific (Pittsburgh, 
PA) and Invitrogen Corporation (Carlsbad, CA), respectively. Ethanol was bought 
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from University of Missouri ChemStores (Columbia, MO) and N-
Hydroxysuccinimide (NHS) from Pierce Protein Research Products (Rockford, 
IL). 
 
3.2.2 Tissue Harvest and Decellularization 
 Porcine aortas were harvested immediately following euthanasia of swine 
after a laboratory exercise at the University Of Missouri School Of Medicine.  
Bovine carotid arteries were collected from the University of Missouri abattoir at 
the time of euthanasia.  Tissue was immersed in distilled water to immediately 
start the decellularization process.  Decellularization was performed using a 
protocol adapted from previously published arterial decellularization protocols. [8, 
9]  Arteries were cleaned of blood and any excess surrounding tissue and then 
immersed in distilled water for 24 hours at 4 ° C to rupture cell membranes.  
Next, the vessels were treated with 0.025% trypsin EDTA (ATCC) diluted in 
Dulbecco’s phosphate buffered saline (dPBS; ATCC) for 24 hours at 37 °C.  The 
tissue was then put into a solution of 1% Triton X-100 (Sigma) and 0.1% 
ammonium hydroxide (Fisher) in distilled water for 72 hours at 4 °C to remove 
nuclear components and lyse cell membranes and cytoplasmic proteins.  The 
tissue was immersed in a solution of Eagle’s Minimum Essential Medium 
(EMEM; ATCC) 10% (v/v) horse serum and PennStrep (200 U/mL) to deactivate 
any remaining trypsin for 24 hours at 37 °C.  Tissue was washed for 24 hours in 
distilled water at 4 °C and for 48 hours in PBS at 4 °C, changing the PBS to fresh 
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solution at 24 hours.  All of these steps were done with mechanical agitation on a 
stir plate.   
 
3.2.3 Crosslinking and Sterilization 
 Specific experimental groups are listed with their respective experiments.  
As these were just initial studies the groups varied, but all had the same basic 
preparations.  Tissue was crosslinked using a protocol publish by Deeken et al. 
[10].  The crosslinking solution was composed of a 50:50 (v/v) solution of 
acetone and PBS (pH=7.4) with 2mM EDC and 5mM NHS. The EDC was 
dissolved in a small volume of MES with 0.5M NaCl (pH 6.) and the NHS in a 
small volume of DMF.  The solutions were immediately mixed together and 
added to the acetone/PBS solution. Treatment groups requiring crosslinking were 
reacted with this solution at ambient temperature for 15 minutes to activate the 
carboxyl groups present on the collagen molecules.  After 15 minutes the 
crosslinking solution was withdrawn and 20 nm (2.8x1012 particles/mL) AuNPs 
were added at a concentration of 4 times the stock solution.  They were amine 
functionalized and added to their respective experimental tissue with PBS.  The 
solely crosslinked tissue group was put into PBS after 15 minutes.  All groups 
were incubated for 24 hours with gentle agitation followed by two 24 hours rinses 
in PBS.  Specimens were sterilized by incubating tissue in an aqueous solution of 
0.1 %(v/v) peracetic acid with 1.0M NaCl for 30 minutes followed by two 24 hour 
sterile PBS rinses.  All steps were performed at ambient temperature with 
shaking.   
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3.2.4 Cell Culture 
 L-929 murine fibroblast cells (ATCC – Manassas, VA) were cultured in 
EMEM supplemented with 10% (v/v) horse serum and 200 U/mL penicillin-
streptomycin solution in an incubator at 37 °C and 5% CO2. Primary umbilical 
vein endothelial cells, normal, human, pooled (ATCC PCS-100-013) were 
cultured Vascular Cell Basal Medium (ATCC PCS-100-030) supplemented with 
Microvascular Endothelial Cell Growth Kit-BBE (ATCC PCS-110-040) and 
Penicillin (10 u/mL) –streptomycin (10 µg/mL)-amphotericin B (25 ng/mL) solution 
(ATCC PCS-999-002). 
 
3.2.5 Biocompatibility of Porcine Tissue with Fibroblasts 
Experimental Groups: 
1) Decellularized tissues (Decell): porcine aortic tissues that underwent the 
decellularization protocol.  n=21  
2) Crosslinked tissues (XLink): decellularized porcine aortic tissues that were 
crosslinked as previously described.  n=19 
3) 4x 20nm AuNP tissues (4x AuNP): decellularized porcine aortic tissues that 
were crosslinked with 20 nm gold nanoparticles at four times the stock solution 
(2.8x1012 particles/mL) in combination with EDC and NHS.  n=20 
Cell proliferation Reagent WST-1 (Roche Diagnostics Corporation, 
Indianapolis, IN) was used to compare the biocompatibility of the experimental 
groups.  Each group had an n as described above and an additional two 
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scaffolds that were not seeded for use as standards.  Culture medium with the 
WST-1 reagent and no cells served as the blank.  The 1 cm tissue discs were 
incubated in individual wells of a 48 well plate at 37 °C and 5% CO2 in EMEM for 
24 hours at 37 °C before being seeded with 3 x 104 L-929 murine fibroblasts/well.  
After 2 days the scaffolds were moved to new 48-well plates to ensure cellular 
attachment to the scaffolds only.   All scaffolds were incubated for 3 days at 37 
°C and 5% CO2 with half the media in each well replaced every 24 hours.  WST-
1 reagent was then added to each well and the plates were incubated for 6 
hours.  100 µl was removed, placed into a 96-well microplate, and read by a BIO-
Rad Model 680 Microplate Reader (Bio-Rad Laboratories Hercules, CA).  The 
percent viability was calculated by normalizing the resulting values by the 
average absorbance of the decellularized group.  The amount of formazan 
created in the reaction between metabolically active cells and the tetrazolium 
salts correlated with the number of metabolically active cells and was quantified 
using UV-Vis absorbance measurements with higher absorbance values 
representing more metabolically active cells and greater biocompatibility.   
 
3.2.6 Cell Proliferation of Fibroblasts on Porcine Tissue 
Experimental Groups: 
1) Decellularized tissues (Decell): porcine aortic tissues that underwent the 
decellularization protocol.  n=6  
2) Crosslinked tissues (XLink): decellularized porcine aortic tissues that were 
crosslinked as previously described.  n=6 
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3) 4x 20nm AuNP tissues (4x AuNP): decellularized porcine aortic tissues that 
were crosslinked with 20 nm gold nanoparticles at four times the stock solution 
(2.8x1012 particles/mL) in combination with EDC and NHS.  n=6 
Quant-iT™ PicoGreen® dsDNA Reagent (Invitrogen Corporation, Carlsbad, CA) 
was used to assess cell proliferation (n = 6 per group at each time point).  This 
assay allows for quantification of dsDNA content which can be directly correlated 
to the amount of cellular growth on the scaffold.  The 1 cm tissue discs were 
incubated in individual wells of a 48 well plate at 37 °C and 5% CO2 in EMEM for 
24 hours at 37 °C before being seeded with 3 x 104 L-929 murine fibroblasts/well.  
All scaffolds were incubated at 37 °C and 5% CO2   for the 7, 10, and 14 day 
time points.  After 2 days the scaffolds were moved to new 48-well plates to 
ensure cellular attachment to the scaffolds only.  The media was changed out 
every other day.  At 7 and 10 days post cell seeding the appropriate scaffolds 
were removed, rinsed with 5mL sterile PBS, placed in 1.5 mL microcentrifuge 
tubes, and frozen at - 70 C.  Samples were lypholized for 24 hours and then the 
dry mass of each scaffold was determined.  Each sample was subjected to a 
papain digestion buffer of 125 µg/mL on a buffer of sterile PBS with 5mM 
cysteine-HCl and 5mL Na2 EDTA for 24 hours at 60 °C.   Each sample was put 
in 4 mL cuvettes then diluted with 1X TE buffer and the PicoGreen dsDNA 
reagent.  The cuvettes were incubated at in the dark at ambient temperature for 5 
minutes.  Fluorescence readings were taken at 520 nm using 480 nm excitation 
on a FluoroMax-3 spectrofluorometer (HORIBA Jobin Yvon, Inc., Edison, NJ).  A 
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Lambda DNA standard curve was used to determine the DNA concentrations for 
the samples.  Each concentration was normalized by the dry mass of the sample.   
 
3.2.7 Biocompatibility of Bovine Tissue with Endothelial Cells 
Experimental Groups: 
1) Decellularized tissues (Decell): bovine carotid arteries that underwent the 
decellularization protocol.  n=9 
2) Crosslinked tissues (XLink): decellularized bovine carotid arteries that were 
crosslinked as previously described.  n=9 
3) 4x 100nm AuNP tissues (4x AuNP): decellularized bovine carotid arteries that 
were crosslinked with 20 nm gold nanoparticles at four times the stock solution 
(2.8x1012 particles/mL) in combination with EDC and NHS.  n=9 
Cell proliferation Reagent WST-1 was used to compare the 
biocompatibility of bovine carotid tissue.  Each group had an n=9 and an 
additional scaffold that was not seeded for use as a standard.  Culture medium 
with the WST-1 reagent and no cells served as the blank.  The tissue discs were 
incubated at 37 °C and 5% CO2 in Vascular Cell Basal Medium (ATCC PCS-
100-030) supplemented with Microvascular Endothelial Cell Growth Kit-BBE 
(ATCC PCS-110-040) and Penicillin (10 u/mL) –streptomycin (10 µg/mL)-
amphotericin B (25 ng/mL) solution (ATCC PCS-999-002) for 24 hours in 
individual wells of a 48 well microplate.  After 24 hours the media was removed 
and each well was seeded with primary umbilical vein endothelial cells, normal, 
human at a concentration of 3 x 104 cells/mL.  After 2 days the scaffolds were 
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moved to new 48-well plates to ensure cellular attachment to the scaffolds only.   
All scaffolds were incubated for 7 days at 37 °C and 5% CO2 with half the media 
in each well replaced every 24 hours.  WST-1 reagent was then added to each 
well and the plates were incubated for 6 hours.  100 µl was removed at 6 hours 
and placed into a 96-well microplate and read by a BIO-Rad Model 680 
Microplate Reader (Bio-Rad Laboratories Hercules, CA).  The percent viability 
was calculated by normalizing the resulting values by the average absorbance of 
the decellularized group.   
 
3.2.8 Mechanical Testing of Porcine Versus Bovine Tissue 
Experimental Groups: 
1) Native Porcine Carotid Artery: freshly harvested porcine carotid artery n=6 
2) Decellularized Porcine Carotid Artery: porcine aortic tissues that underwent 
the decellularization protocol. n=6 
3) Crosslinked Porcine Carotid Artery: decellularized porcine aortic tissues that 
were crosslinked as previously described. n=4 
4) Native Porcine Aorta: freshly harvested porcine aorta. n=4 
5) Decellularized Porcine Aorta: porcine carotid arteries that underwent the 
decellularization protocol. n=6 
6) Crosslinked Porcine Aorta: decellularized porcine carotid arteries that were 
crosslinked as previously described. n=6 
7) Native Bovine Carotid Artery: freshly harvested bovine carotid artery. n=10 
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8) Decellularized tissues: bovine carotid arteries that underwent the 
decellularization protocol. n=6 
9) Crosslinked tissues: decellularized bovine carotid arteries that were 
crosslinked as previously described. n=5 
AuNP conjugated tissues were not tested as no significant differences 
were found between tissues with and without them.  That data can be found in 
Chapter 4 of this dissertation.  The vessels were tested in the longitudinal 
direction.  Each piece was 4 cm by 1 cm and notched to reduce the width of the 
specimen to approximately 0.5 cm and create a stress concentration in the 
center of the specimen and thus prevent failure in the grip.  A mechanical testing 
system (Instron TA.XT2, Texture Technologies, Corporation, Scarsdale, NY) 
strained the specimens until failure.  The tensile strength at yield was calculated 
by dividing the maximum load, Fmax, by the original cross-sectional area, A, of 
the specimen.  The modulus of elasticity E, was determined from the slope of a 
line fit to the stress versus strain curve of each specimen.   
 
3.2.9 Statistical Analysis 
GraphPad Prism v4.0 (GraphPad Software, Inc., San Diego, CA) was 
used to analyze experimental data. One-way analysis of variance (ANOVA) with 
a 95% confidence interval was conducted followed by a Tukey-Kramer post-test 
to determine significant differences between means of the experimental groups 
for the mechanical testing and biocompatibility assays.  A two-way ANOVA was 
used to analyze the cell proliferation assay with regards to both the differing time 
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points and experimental groups.  Values are reported and graphed as the mean 
± standard error of the mean. 
 
3.3 Results 
3.3.1 Biocompatibility of Porcine Tissue with Fibroblasts 
 The WST-1 assay showed no significant differences between any of the 
groups when the percent viability of the experimental groups were compared to 
the decellularized tissue, indicating no significant changes in viability with the use 
of crosslinking or nanoparticles.   Significance was set at P<0.05 and for this 
experiment P= 0.884.  Figure 3.1 shows percent viability of each experimental 
group relative to the decellularized, with specific values in Table 3.1. 
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Table 3.1 Summary of WST-1 Assay data with fibroblasts 
Experimental Group % Viability compared to Decell 
Decellularized Porcine Tissue 100.0% ± 7.5% 
Crosslinked Porcine Tissue 95.5% ± 8.7% 
Crosslinked with 4x 100nm AuNPs 101.9% ± 11.1% 
 
 
 
 
Figure 3.1 Cell Proliferation Reagent WST-1 assay on porcine aortas showing 
percent viability relative to the decellularized tissue, indicating no significant 
changes in viability with the use of crosslinking or nanoparticles.   
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3.3.2 Cell Proliferation of Fibroblasts on Porcine Tissue 
 The fluorescence intensity of the Quant-iTTM PicoGreen® dsDNA reagent 
quantified cell proliferation and was recorded for the experimental material 
digests after being cultured with L-929 mouse fibroblasts.  The lamda DNA 
standard curve was used to calculate a curve with an r2 value of 0.9699.  The 
data was normalized to the dry weight of each scaffold (see Table 3.2) and the 
nanograms of DNA per milligram scaffold was calculated and graphed in Figure 
3.2.  There were no significant differences (p<0.05) between each group on a 
specific day, however there was a significant increase within groups between 
days 7 and 10.  This increase shows that the cells continue proliferating as they 
should, and do not start dying out.  The lack of significant differences between 
experimental groups at each time point shows that the crosslinking and addition 
of AuNPs does not have a negative effect on cell proliferation. 
 
Table 3.2 Summary of PicoGreen Data of fibroblasts on porcine tissue showing 
scaffold dsDna content (ng/mg dry scaffold weight) 
 
Experimental Group Day 7 Day 3 
Decellularized Porcine Aorta 3.90 ± 0.253 7.322 ± 0.339 
Crosslinked Porcine Aorta 3.028 ± 0.591 7.683 ± 0.774 
Crosslinked with 4x 100nm AuNPs 4.015 ± 0.993 7.402 ± 0.552 
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Figure 3.2 The results of the PicoGreen Assay using porcine aortas and 
fibroblast cells showing that each group had a significant increase (p<0.05) 
between days 7 and 10.   
 
 
3.3.3 Biocompatibility of Bovine Tissue with Endothelial Cells 
 The WST-1 assay showed no significant differences between any of the 
groups when the percent viability of the experimental groups were compared to 
the decellularized tissue, indicating no significant changes in viability with the use 
of crosslinking or nanoparticles.   Significance was set at P<0.05 and for this 
experiment P= 0.624.  Figure 3.3 shows percent viability of each experimental 
group relative to the decellularized, with specific values in Table 3.3.   
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Table 3.3 Summary of WST-1 Assay data of endothelial cells on bovine tissue 
Experimental Group % Viability compared to Decell 
Decellularized Bovine Carotid 100.0% ± 15.0% 
Crosslinked Bovine Carotid 80.2% ± 14.2% 
Crosslinked with 4x 100nm AuNPs 89.4% ± 13.7% 
 
 
 
 
Figure 3.3 Cell Proliferation Reagent WST-1 assay on bovine tissue showing 
percent viability relative to the decellularized tissue, indicating no significant 
changes in viability with the use of crosslinking or nanoparticles.   
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3.3.4 Mechanical Testing of Porcine Versus Bovine Tissue 
 Porcine aortic and carotid tissue was compared to bovine carotid tissue to 
compare the mechanical properties of each.  The tensile stress at maximum 
load, the modulus of elasticity, and the percent tensile strain at maximum load 
were calculated to determine how each behaved.  Table 3.4 contains the values 
for each experimental group.  For the modulus of elasticity,  Porcine Decell 
Carotid, Porcine X link Carotid, Porcine Native Aorta, Porcine Decell Aorta, and 
Porcine Xlink Aorta were significantly lower (p<0.01) than Bovine Native Carotid.  
Porcine Decell Carotid was significantly (p<0.05) lower than Bovine Xlink Carotid.  
Porcine Decell Carotid, Porcine Decell Aorta, and Porcine Xlink Aorta were 
significantly lower (P<0.01) than Bovine Carotid Decell.  These differences can 
be seen in Figure 3.4a.  For tensile stress at max load, Porcine Decell Carotid 
and Porcine Decell Aorta were significantly lower (p<0.01) than Bovine Native 
Carotid.  Porcine Native Carotid, Porcine Decell Carotid,  Carotid Porcine Native 
Aorta, Porcine Decell Aorta, and Porcine Xlink Aorta were significantly lower 
(p<0.01) than Bovine Decell Carotid.  Porcine Decell Carotid, Porcine Native 
Aorta, Porcine Decell Aorta, and Porcine Xlink Aorta were significantly lower 
(p<0.01) than Bovine Xlink Carotid.  These differences can be seen in Figure 
3.4b.   
 
 
 
 
51 
 
 
 
 
Table 3.4 Modulus of Elasticity (MPa) and Tensile Stress at Max (MPa) for each 
experimental group 
 
 Modulus of Elasticity 
(MPa) 
Tensile Stress at Max 
(MPa) 
PCNative 15.07 ± 2.60 1.15 ± 0.17 
PCDcell 3.22 ± 0.75 0.57 ± 0.07 
PCXlink 9.63 ± 1.26 1.33 ± 0.43 
PANative 9,74 ± 2.67 0.57 ± 0.09 
PADcell 6.29 ± 2.63 0.57 ± 0.11 
PAXlink 5.73 ± 0.68 0.65 ± 0.06 
BCNative 26.61 ± 3.27 1.87 ± 0.27 
BCDecell 22.81 ± 4.70 2.62 ± 0.41 
BCXlink 17.72 ± 3.04 2.44 ± 0.30 
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3.4a) Modulus of Elasticity 
 
3.4b) Tensile Stress at Max Load
 
Figure 3.4 Mechanical testing on porcine and bovine tissues.  White shapes 
denote a value significantly lower than the matching black shape on each graph. 
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3.4 Discussion and Conclusions 
 Preliminary studies were done using porcine aortic tissue and murine 
fibroblasts to test the basic biocompatibility of the material and its various 
modifications.  L-929 murine fibroblasts are a very commonly used cell line and 
the studies done here prove that our modifications do not kill the fibroblast cells.  
This was the basis for our later testing with more sensitive endothelial cell line, 
which is the type of cell we hope will populate the surface of our biomaterial in 
vivo.  While the decellularization process used here has been previously 
published [8, 9], cell culture studies using a basic fibroblast cell line were useful 
to ensure we were performing the protocol correctly and not leaving any 
potentially harmful chemicals in the material.  Crosslinking with zero length 
crosslinkers has become more common as the use of glutaraldehyde 
crosslinkers have been shown to calcify when implanted. [11, 12]   The zero 
length crosslinking utilized here has shown that it does not cause any cytotoxicity 
and allows cells to proliferate as well as experimental groups without 
crosslinking.  The final modification tested was the use of AuNPs.  AuNPs have 
been shown in vitro to enhance cellular proliferation, reduce bacterial adhesion, 
and reduce reactive oxygen species when conjugated to polyethylene 
terephthalate.[13]  Here we tested them at a high concentration to make sure we 
wouldn’t see cytotoxicity.  From these preliminary tests we concluded that the 
material was safe enough to try with endothelial cell culture assays.   
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 Animal tissue is used in numerous medical applications such as heart 
valves [14-17], blood vessels [18-20], urinary bladder [21], bovine pericardium, 
and many others [22].  Bovine pericardium is used as a vascular and cardiac 
patch material.  We wanted to look at bovine carotid vessels as they are larger 
than the porcine carotid arteries, but still thinner than the porcine aortas.  The 
biocompatibility study showed that the bovine carotid tissue had no detrimental 
effect on human endothelial cells.  The mechanical studies indicate that the 
strengths of bovine and porcine tissue vary between animal species and artery 
type.  However there were no significant differences between material 
modifications (decellularizing, crosslinking) and the native tissue within groups of 
the same tissue type.  This indicates that our modifications are not changing the 
properties of the native tissue, which shows great promise for our biomaterial.   A 
biomaterial with a higher elastic modulus will be stiffer.  Overall the bovine tissue 
was generally stiffer than the porcine tissue.  When implanted into a vessel this 
would allow for less stretch of the bovine patch and could indicate more 
deformation of the hemodynamic flow pattern.  It has been shown that a more 
compliant graft may match mechanical and flow parameters better than a less 
compliant material [23].  Bovine arterial tissue might still be a promising material 
for other cardiovascular applications such as heart valve leaflets, though.  The 
tensile stress at max load indicates the point at which the material fails 
completely.  Again we saw that overall the porcine tissue failed at a lower force 
per unit area than the bovine tissue.  This is not necessarily a negative 
characteristic, and later we saw that the porcine material still withstands great 
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vascular pressures in vivo.  These conclusions leave the door open for further 
testing of the bovine vessels.  Bovine and porcine vessels should be compared 
to human native vessels, something we were unable to do due to availability of 
such.  Suture pullout testing of the biomaterial is included in Chapter 6 of this 
dissertation. The decision was made to move forward with the porcine tissue as 
the bovine showed no real advantage over it and was much more difficult to 
obtain.   
 Overall these preliminary studies gave us good basic information on the 
characteristics of our bases for a composite biomaterial as well as about the 
surface modifications made to that material.  Further in vitro and in vivo testing of 
these materials is available in the next several chapters of this dissertation.   
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Chapter Four 
MECHANICAL AND IN VITRO CHARACTERIZATION OF 
DECELLULARIZED PORCINE ARTERIAL TISSUE 
CONJUGATED WITH GOLD NANOPARTICLES AS A 
VASCULAR REPAIR MATERIAL 
4.1 Abstract 
There is a need for improved vascular and cardiac repair materials.  These 
materials must be biocompatible and resist rupture, calcification, and 
degradation.  Materials of biological origin such as decellularized tissue have 
shown the most promise for achieving these characteristics; however, they still 
suffer from poor cellular integration and mechanical weakness as compared to 
the native structures.  This study investigated the effects of decellularization, 
crosslinking, and conjugation with gold nanoparticles (AuNP) on porcine aortic 
tissue for use as a vascular repair material.  Histology and scanning electron 
microscopy were performed and confirmed the removal of immunogenic nuclear 
remnants, confirmed little change in structure after decellularization, and 
confirmed the presence of the AuNPs on the material.  Mechanical testing was 
performed which indicated no significant differences in mechanical properties 
between the native vessel and the modified vessels.  Cell culture studies were 
performed which demonstrated that the modified material was biocompatible.  
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This study confirmed that the decellularized scaffolds maintain the important 
native tissue characteristics and that crosslinking and the addition of AuNPs 
achieves biocompatible tissue scaffolds.  
 
4.2 Introduction 
Vascular disease is one of the leading causes of morbidity and mortality in the 
United States [1-3].  It includes vessel occlusion due to atherosclerosis, coronary 
artery occlusion, peripheral artery disease, and stroke with vessel occlusion.  
Many of these conditions require surgical interventions such as carotid 
endarterectomy with patch angioplasty, which involve materials that can replace 
or enhance damaged vessels.  There are numerous types of material available, 
and all have their own strengths and weaknesses. [4, 5]  A repair material needs 
to display the same mechanical and biologic characteristics as the native tissue 
while not causing an immune reaction, but rather allowing for the material to be 
integrated into the host [1-3, 6, 7] .  
Current synthetic and biologic scaffolds can cause a host reaction 
including inflammation, calcification, and infection [4, 8-12].  Synthetic materials 
such as expanded polytetrafluoroethylene (ePTFE) and Dacron (polyethylene 
terephthalate) are currently used for vascular patches.  These materials possess 
good mechanical properties and have demonstrated acceptable in vivo durability.  
The problems with the synthetic materials are their inability to promote 
endothelial cell migration and remodeling while their foreign body response can 
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lead to chronic phase inflammation [13].  Another shortcoming is the inability of 
the synthetic material to “grow”, which is especially problematic with pediatric 
patients.  Biological patches, such as bovine pericardium, are an alternative to 
synthetic materials.  Biologic materials used in a vascular environment tend 
towards mechanical failure, re-stenosis, and calcification [13].  In particular the 
use of glutaraldehyde crosslinkers has been shown to promote this process. 
However, utilizing a natural tissue structure allows for a three-dimensional 
scaffold that could enhance remodeling while providing mechanical strength.   
 The challenge to successful graft repair is how to promote constructive 
remodeling without sacrificing structural integrity prior to regeneration of 
pressure-bearing neotissue. To maintain the necessary mechanical properties, 
many biologic materials are crosslinked such that they are resistant to 
degradation.  An earlier study demonstrated longer degradation times in vivo with 
crosslinked scaffolds as compared to non-crosslinked scaffolds [14].  The 
increased degradation time allows the cells to infiltrate and begin building their 
own matrix.  However, crosslinking can drastically alter the overall micro-
environment, resulting in a stiffer material, and the toxicity of crosslinking agents 
such as glutaraldehyde is a concern [15].  Additionally, the host remodeling 
response is distinctly altered from constructive remodeling to fibrous 
encapsulation and chronic inflammation [16].  Therefore to achieve successful 
constructive remodeling, crosslinking must be minimized so that the patch can 
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undergo slow degradation while promoting tissue regeneration and maintaining 
structural integrity. 
In recent studies, crosslinking was combined with conjugating amine 
functionalized gold nanoparticles (AuNP) to acellular tissue scaffold to enhance 
biocompatibility and mitigate not only adverse crosslinking effects but also 
decrease the amount of crosslinkers needed. Previous research performed in our 
lab has shown that AuNPs improve performance including decreasing 
degradation [17, 18].  Cell culture studies have shown increase cell proliferation, 
as well as reducing reactive oxygen species which could reduce the inflammatory 
response [19-21].  In a study by Chou et al., poly(ether)urethane containing gold 
or silver nanoparticles where shown to reduce surface degradation through free 
radical scavenging while also improving cellularity [22]. 
There is a critical need for effective vascular patches for the treatment of 
stenosis in diseased carotid or femoral blood vessels. The purpose of this study 
was to investigate the use of decellularized porcine arteries as a possible 
vascular patch.  The use of decellularized arterial blood vessels is advantageous 
since improved hemodynamics is achievable by replacing part of a disease artery 
with an actual arterial patch which would better mimic the properties of natural 
arteries.  To reduce the negative effects of crosslinking, AuNPs were conjugated 
to the decellularized arteries using a zero-length crosslinker.  It was hypothesized 
that AuNP-conjugated blood vessels would help maintain the natural tissue 
properties such as strength, stiffness, and open microstructure while providing 
62 
 
good biocompatibility.  The properties of these AuNP-blood vessels were 
investigated using histology, scanning electron microscopy, mechanical testing, 
and cell culture assays.   
 
4.3 Materials and Methods 
4.3.1 Tissue Harvest and Decellularization 
Porcine aortas were harvested immediately following euthanasia of swine 
after a laboratory exercise at the University of Missouri School of Medicine using 
a protocol adapted from a previously published protocol [23, 24].  They were 
cleaned of blood and any excess surrounding tissue and then immersed in 
distilled water for 24 hours at 4 ° C to rupture cell membranes.  Next, the vessels 
were treated with 0.025% trypsin EDTA (ATCC) diluted in Dulbecco’s phosphate 
buffered saline (dPBS; ATCC) for 24 hours at 37 °C.  The tissue was then put 
into a solution of 1% Triton x-100 (Sigma) and 0.1% ammonium hydroxide 
(Fisher) in distilled water for 72 hours at 4 °C to remove nuclear components and 
lyse cell membranes and cytoplasmic proteins.  The tissue was then put into a 
solution of Eagle’s Minimum Essential Medium (EMEM; ATCC) 10% (v/v) horse 
serum and PennStrep (200 U/mL) to deactivate any remaining trypsin for 24 
hours at 37 °C.  Tissue was washed for 24 hours in distilled water at 4 °C and 
washed for 48 hours in PBS at 4 °C, changing the PBS to fresh solution at 24 
hours.  All of these steps were done with mechanical agitation on a stir plate.   
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4.3.2 Treatment Groups   
We fabricated and characterized five treatment groups as shown below: 
1) Decellularized tissues: porcine aortic tissues that underwent the 
decellularization protocol.   
2) Crosslinked tissues: decellularized porcine aortic tissues that were crosslinked 
with the chemical crosslinkers 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
(EDC) and N-hydroxysuccinimide(NHS).  
3) 4x 20nm AuNP tissues: decellularized porcine aortic tissues that were 
crosslinked with 20 nm gold nanoparticles (Ted Pella) at four times the stock 
solution (2.8x1012 particles/mL) in combination with EDC and NHS (sterilized 
using peracetic acid for SEM).   
4) 4x 100nm AuNP tissues:   decellularized porcine aortic tissues that were 
crosslinked with 100nm gold nanoparticles (Ted Pella) at four times the stock 
solution (2.24a1010 particles/mL) in combination with EDC and NHS and 
sterilized using peracetic acid. 
5) Natural tissues: natural, untreated porcine aortic tissue that did not undergo 
decellularization or crosslinking. 
 The 20 and 100 nm sized gold nanoparticles were chosen based on previous 
experience with these sizes as biocompatible, non-cytotoxic nanoparticles [17].   
Initially, only 20 nm AuNPs were tested, but concerns with their sterilization led to 
the use of the 100 nm AuNPs. 
 
64 
 
4.3.3 Crosslinking 
Circular pieces 1 cm in diameter of decellularized tissue were placed into 
a crosslinking solution (50:50 (v/v) of acetone and PBS with EDC and NHS.  The 
tissue was incubated in the solution for 15 minutes at ambient temperature.  After 
the incubation the crosslinking solution was withdrawn and nanoparticles were 
added.  The AuNPs were first functionalized using a solution of 2-
mercaptoethylamine.  The crosslinked tissue group remained in the crosslinking 
solution.  All types of tissue were incubated for 24 hours at ambient temperature 
with gentle agitation followed by two 24 hours rinses with PBS.   
Specimens used for cell culture, sterility testing, SEM and mechanical tests were 
incubated in an aqueous solution of 0.1%(v/v) peracetic acid with 1.0M NaCl for 
30 minutes followed by two 24 hour sterile PBS rinses.  All steps were performed 
at ambient temperature with shaking.   
 
4.3.4 Cell Culture 
  Primary umbilical vein endothelial cells, normal, human, pooled (ATCC 
PCS-100-013) were cultured Vascular Cell Basal Medium (ATCC PCS-100-030) 
supplemented with Microvascular Endothelial Cell Growth Kit-BBE (ATCC PCS-
110-040) and Penicillin (10 u/mL) –streptomycin (10 µg/mL)-amphotericin B (25 
ng/mL) solution (ATCC PCS-999-002). 
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4.3.5 Sterilization 
 Sterilization of the scaffolds was tested at the University of Missouri 
Veterinary Medicine Diagnostic Lab.  Sterilized scaffolds were tested at aerobic 
and anaerobic conditions, at room temperature, 35 °C, and in both brain heart 
infusion broth and thioglycollate broth.  Samples were held for 14 days to watch 
for bacterial growth.   
 
4.3.6 Histology 
 Longitudinal and cross-sectional samples from sample groups 1-3 and 5 
were embedded in paraffin, cut with a microtome at 5 µm and stained with 
hematoxylin and eosin (H&E).  Viewing was performed on a Zeiss Axiophot (Carl 
Zeiss Microimaging, Inc., Thornwood, NY) and photographs were taken using an 
Olympus DP70 (Olympus America Inc., Center Valley, PA) camera with DP 
Manager Version 1.21.107 as the acquisition software. Initially the slides were 
viewed at 10x and 20x to get an overall sense of the tissue. Representative 
areas were then photographed at a magnification of 10x. 
 
4.3.7 Scanning Electron Microscopy 
Tissue scaffolds were placed in a primary fixation in 0.1 M sodium 
cacodylate buffer containing 2% glutaraldehyde and 2% paraformaldehyde at 4 
°C.  This was followed by three five minute 0.1 M sodium cacodylate buffer rinses 
at ambient temperature on a rocker.  Samples were then rinsed three times in 
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Milli-Q ultrapure water at ambient temperature and five minutes per rinse.  Tissue 
discs were dehydrated in a series of graded ethanol rinses (20%, 50%, 70%, 
90%, and three rinses in 100%).  This was performed under vacuum in a 
microwave at 100W and 40s per rinse.  They were critical point dried (Auto-
Samdri 815 critical point dryer – Tousimis Research Corporation, Rockville, MD) 
and mounted on SEM stubs with carbon tape.  They were carbon coated in a 950 
Turbo Evaporator (EM Technologies, LTD., Kent, England).  Scaffolds were 
viewed using a Quanta 600F Environmental SEM (FEI Company, Hillsboro, OR) 
at 15kV with backscatter imaging and gold was identified using energy dispersive 
X-ray spectroscopy during viewing.   
 
4.3.8 Mechanical Testing 
Specimens of groups 1 (unsterilized n=6, sterilized n=6), group 2 
(unsterilized n=6, sterilized n=8), group 3 (n=3), and group 5 (n=4) were tested.  
Groups 1 and 2 had subsets of sterilized and unsterilized specimens.  The 
vessels were tested in the longitudinal direction.  Each piece was 4 cm by 1 cm 
and notched to reduce the width of the specimen to approximately 0.5 cm in 
order to create a stress concentration in the center of the specimen and thus 
prevent failure in the grip.  A mechanical testing system (Instron TA.XT2, Texture 
Technologies, Corporation, Scarsdale, NY) strained the specimens until failure.  
The tensile strength at yield was calculated by dividing the maximum load, Fmax, 
by the original cross-sectional area, A, of the specimen.  The modulus of 
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elasticity, E, was determined from the slope of a line fit to the stress versus strain 
curve of each specimen.  Group 4 was not tested for mechanical properties due 
to 1) Group 4 was added on after concerns with the 20 nm AuNP sterility 
problems (they were dissolving during sterilization) and 2) previous data 
demonstrated that the size of the AuNPs did not affect mechanical properties[17].   
 
4.3.9 Biocompatibility 
Cell proliferation Reagent WST-1 (Roche Diagnostics Corporation, 
Indianapolis, IN) was used to compare the biocompatibility of the tissue groups 1, 
2, and 4.  Each group had an n=11 and an additional two scaffolds that were not 
seeded for use as standards.  Culture medium with the WST-1 reagent and no 
cells served as the blank.  The tissue discs were incubated at 37 °C and 5% CO2 
in Vascular Cell Basal Medium (ATCC PCS-100-030) supplemented with 
Microvascular Endothelial Cell Growth Kit-BBE (ATCC PCS-110-040) and 
Penicillin (10 u/mL) –streptomycin (10 µg/mL)-amphotericin B (25 ng/mL) solution 
(ATCC PCS-999-002) for 24 hours in individual wells of a 48 well microplate.  
After 24 hours the media was removed and each well was seeded with Primary 
umbilical vein endothelial cells, normal, human at a concentration of 3 x 104 
cells/mL.  After 2 days the scaffolds were moved to new 48-well plates to ensure 
cellular attachment to the scaffolds only.   All scaffolds were incubated for 7 days 
at 37 °C and 5% CO2 with half the media in each well replaced every 24 hours.  
WST-1 reagent was then added to each well and the plates were incubated for 6 
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hours.  100 µl was removed at 6 hours and placed into a 96-well microplate and 
read by a BIO-Rad Model 680 Microplate Reader (Bio-Rad Laboratories 
Hercules, CA).  The amount of formazan created in the reaction between 
metabolically active cells and the tetrazolium salts correlates with the number of 
metabolically active cells.  The amount of formazan was quantified using UV-Vis 
absorbance measurements with higher absorbance values representing more 
metabolically active cells and greater biocompatibility.   
 
4.3.10 Cell Proliferation 
Quant-iT™ PicoGreen® dsDNA Reagent (Invitrogen Corporation, 
Carlsbad, CA) was used to assess cell proliferation between groups 1, 2, and 4 
(n=9 per group per time point).  This assay allows for quantification of dsDNA 
content which can be directly correlated to the amount of cellular growth on the 
scaffold.  The tissue discs were incubated at 37 °C and 5% CO2 in Vascular 
Basal Cell Medium (ATCC PCS-100-030) supplemented with Microvascular 
Endothelial Cell Growth Kit-BBE (ATCC PCS-110-040) and Penicillin (10 u/mL) –
streptomycin (10 µg/mL)-amphotericin B (25 ng/mL) solution (ATCC PCS-999-
002) for 24 hours in individual wells of three 48 well microplates- one for each 
time point.  After 24 hours the media was removed and each well was seeded 
with 1 mL of primary umbilical vein endothelial cells, normal, human at a 
concentration of 3 x 104 cells/mL.  All scaffolds were incubated at 37 °C and 5% 
CO2   for the 7, 10, and 14 day time points.  After 2 days the scaffolds were 
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moved to new 48-well plates to ensure cellular attachment to the scaffolds only.  
The media was changed out every three days.  At 7, 10, and 14 days post cell 
seeding the appropriate scaffolds were removed, rinsed with 5mL sterile PBS, 
placed in 1.5 mL microcentrifuge tubes, and frozen at - 70 ®C.  Samples were 
lypholized for 24 hours and then the dry mass of each scaffold was determined.  
Each sample was subjected to a papain digestion buffer of 125 µg/mL on a buffer 
of sterile PBS with 5mM cysteine-HCl and 5mL Na2 EDTA for 24 hours at 60 °C.   
Each sample was put in 4 mL cuvettes then diluted with 1X TE buffer and the 
PicoGreen dsDNA reagent.  The cuvettes were incubated at in the dark at 
ambient temperature for 5 minutes.  Fluorescence readings were taken at 520 
nm using 480 nm excitation on a FluoroMax-3 spectrofluorometer (HORIBA 
Jobin Yvon, Inc., Edison, NJ).  A Lambda DNA standard curve was used to 
determine the DNA concentrations for the samples.  Each concentration was 
normalized by the dry mass of the sample.   
 
4.3.11 Statistical Analysis 
Statistical analysis of the mechanical testing, WST assay, and PicoGreen 
Assay were performed using GraphPad Prism software, version 4.0 using a one 
way analysis of variance with a 95% confidence interval.  Values are reported 
and graphed as the mean ± standard error of the mean.   
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4.4 Results 
4.4.1 Sterilization 
In scaffolds sterilized in peracetic acid for 30 minutes there was no 
bacterial growth under any of the conditions for two weeks.   
 
4.4.2 Histology 
The H&E staining of natural porcine aortic tissue showed typical arterial 
architecture.  The cross-sections displayed smooth muscle cell nuclei within the 
layers of elastic lamellae in the tunica media.  The tunica adventitia shows 
moderately disrupted layers of collagen and fibroblast nuclei.  After 
decellularization no cellular nuclei or debris can be observed in the tissue.  The 
adventitial layer has a minimal presence.  The layers of elastic lamellae remain 
the same between tissue that is decellularized, crosslinked, and crosslinked with 
gold nanoparticles.  No major structural changes were noted, as can be seen in 
Figure 4.1.   
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Figure 4.1 Histologic findings for porcine aortic tissue (H&E stain, original 
magnification 10x).  
a) Native porcine aorta 
b) Decellularized porcine aorta 
c) Decellularized and crosslinked porcine aorta 
d) Porcine aorta decellularized and crosslinked with AuNPs 
 
4.4.3 Scanning Electron Microscopy 
No major deformations in the scaffold structure were noted on SEM.  
Backscatter and EDS showed the presence of 20 nm and 100 nm AuNPs on 
tissue that was not sterilized.  However after sterilization no 20 nm AuNPs could 
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be detected.  100nm AuNPs were present and subjectively were well dispersed 
over the scaffold as shown in Figure 4.2.  Energy dispersive x-ray spectroscopy 
(EDS) indicated that areas of increased density on backscatter viewing had 
molecular weights equivalent to gold.   
  
Figure 4.2 Scanning electron micrograph using backscatter imaging of 100nm 
AuNP crosslinked scaffold with AuNPs present. 
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4.4.4 Mechanical Testing 
Natural porcine aorta and tissue that was decellularized, crosslinked, crosslinked 
with AuNPs, sterile and non-sterile were compared to one another.  The tensile 
stress at maximum load, the modulus of elasticity, and the percent tensile strain 
at maximum load were calculated and are shown in Figure 4.3 with standard 
error of the mean.  There were no significant differences in between the native 
tissue and the experimental groups. Specific values can be found in Table 4.1.   
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Table 4.1 Summary of mechanical testing data 
 
  
Modulus of 
Elasticity (MPa) 
Mean Tensile 
Strength at 
Yield (MPa) 
Percent Strain 
at Yield (%) 
Native Aorta 9.754 ± 0.2.673 0.573 ± 0.094 19.484 ± 1.869 
Unsterilized 
Decellularized 
Aorta 
6.294 ± 2.632 0.571 ± 0.109 26.404 ± 2.414 
Unsterilized 
Crosslinked 
Aorta 
5.728 ± 0.682 0.646 ± 0.059 22.58 ± 0.957 
Unsterilized 
AuNP 
Crosslinked 
Aorta 
7.936 ± 1.368 0.505 ± 0.031 12.512 ± 1.292 
Sterilized 
Decellularized 
Aorta 
8.310 ± 1.181 0.603 ± 0.078 17.717 ± 0.865 
Sterilized 
Crosslinked 
Aorta  
11.469 ± 1.472 0.855 ± .111 15.148 ± 0.990 
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Figure 4.3 Results of mechanical 
testing showing no significant differences between the native and experimental. 
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4.4.5 Biocompatibility 
  The WST-1 assay showed no significant differences (P>0.05) between 
any of the groups when the percent viability of the experimental groups were 
compared to the decellularized tissue.  The percent viabilities can be compared 
in Figure 4.4 with specific values in Table 4.2. 
 
 
Figure 4.4 Results of WST-1 Assay showing percent viability of the experimental 
groups relative to the decellularized control.  
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Table 4.2 Summary of WST-1 Assay data 
 
 
 
 
 
 
 
4.4.6 Cell Proliferation  
The PicoGreen dsDNA assay quantified cell proliferation.  The data was 
normalized to the dry weight of each scaffold and the nanograms of DNA per 
milligram scaffold was calculated.  The assay showed no significant differences 
between groups at each time point or within groups at different time points.  The 
comparisons between groups at each time point can be found in Figure 4.5 with   
values for each group in Table 4.3.   
 
 
 
 
 
 
 
 
Experimental Group % Viability at 6 hours 
Decellularized Tissue 100.0 ± 3.5% 
Crosslinked Tissue 75.7 ± 2.9% 
Crosslinked with 4x 100nm 
AuNPs 
104.9 ± 3.0% 
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Table 4.3 Summary of PicoGreen dsDNA Assay data 
 
 
 
 
 
Figure 4.5 Results of the PicoGreen dsDNA assay for 7, 10, and 14 days 
showing the DNA content per mg scaffold weight   
 
Scaffolds Day 7 (ng 
DNA/mg scaffold) 
Day 10 (ng 
DNA/mg scaffold) 
Day 14 (ng 
DNA/mg scaffold) 
Decellularized 36.1172 ±  
6.230115 
26.65453 ± 
5.259623 
28.83081 ± 
6.065864 
Crosslinked 22.15774 ± 
5.872915 
30.01409 ± 
2.698935 
24.87589 ± 
3.994903 
Crosslinked 4x 
100nm AuNP 
23.58197 ± 
1.45902 
20.71868 ± 
1.603951 
24.08586 ± 
4.7469 
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4.5 Discussion 
This study characterized vascular patches composed of decellularized 
aortic tissue conjugated with AuNPs nanomaterials.  The use of AuNPs should 
impart beneficial properties such as increase cell attachment and proliferation, 
reduced inflammation and antimicrobial-like features.  Studies using mouse 
fibroblast cells have demonstrated increased cellularity on polymeric scaffolds, 
(polypropylene conjugated to AuNPs), while other studies have shown increased 
proliferation on AuNP-decellularized tissue [17, 25].   Other nanosized materials 
have also shown increased cellularity.  In a study by Rodrigues, et al., nanosize 
hydroxyapatite (HA) conjugated to collagen fibrils demonstrated a significant 
increase in cell proliferation over non-HA collagen scaffolds [26].  Additionally, 
Sumbayev, et al., has demonstrated anti-inflammatory activity in gold 
nanoparticles while in other studies using functionalizing poly(ether)urethane 
(PU) with AuNPs has been shown to reduce oxidation [19, 20, 27].  Gold is an 
electron acceptor so it has the ability to scavenge free radicals, which may 
reduce the inflammatory response.  Studies have also demonstrated the 
bacteriostatic nature of gold nanoparticles.  In a study by Badwaik, et al., sugar-
encapsulated gold nanoparticles were shown to exhibit bactericidal action via a 
disruption of the bacterial cell membrane [28].  The 60 to 120 nm AuNPs had the 
most beneficial effects.   
The use of decellularized blood vessels should impart similar 
biomechanics as the native vessel and thus have similar hemodynamics. 
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However, crosslinking is occasionally needed to increase the biomechanics, 
which can affect the remodeling response.  Additionally, crosslinkers have been 
shown to elicit cytotoxicity, such as with the glutaraldehyde crosslinker during the 
degradation process.  To avoid these problems, we conjugated AuNPs to 
acellular tissue using a zero-length crosslinker, EDC, which has been shown to 
be more cell friendly.  Conjugating AuNPs to acellular scaffolds, as well as 
purified collagen, slows down the degradation which provide more time for 
remodeling and thus maintains its biomechanical strength longer.  It has been 
stated in recent studies that the AuNPs bond to carboxylic acid groups on the 
collagen fibrils which helps disrupt the collagenase binding sites [18].  Therefore, 
less crosslinking is needed to achieve long term stability and thus less changes 
in the natural tissue structure [29].  Additionally, less crosslinking leaves behind a 
more open structure for cellular migration.  The SEM images demonstrated a 
very similar structure to native decellularized tissue.  The intended use of AuNPs 
is not to improve mechanical properties, but to hinder collagenase binding sites 
to prevent premature degradation, as seen in our lab’s previous studies [18].  
Therefore it is imperative to find a correct balance of crosslinking to achieve good 
mechanical properties while still maintaining the native microstructure of the 
scaffold.   
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4.5.1 Histology  
Histology indicates that the decellularization process is feasible; the native 
structure was not destroyed or altered while cells and cellular debris were 
effectively removed leaving behind the extracellular matrix. Decellularized tissue 
as biological repair material is becoming more common.  Preliminary studies 
using swine small intestine submucosa demonstrated no evidence of patch 
related surgical complications in humans [30].  Successful decellularization of the 
arterial tissue was possible as shown through histology.  Also noted was the 
objective lack of change in the structure of the extracellular matrix (ECM) after 
decellularizing and crosslinking.  The removal of the nuclear material from the 
tissue is the first major step in creating a xenograft that will not be rejected by the 
host.  The lack of remnant nuclear material shows the decellularization protocol 
works and thus can remove material that might cause an immune reaction in a 
human.  The removal of the adventitial layer is not concerning as this was 
performed mostly through the removal of outer connective tissue and was 
moderately disrupted even before the decellularization process.   A previous 
study had concerns about the removal of this layer, but our imaging and 
mechanical testing indicated no such concerns [23].  By removing the nuclear 
material, the extracellular matrix remains and is intact for use as a vascular 
patch.  No damage to the structure of the ECM was noted under light microscopy 
or SEM, indicating the decellularization process is not damaging to the scaffold.  
This was also demonstrated through mechanical testing. 
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4.5.2 Scanning Electron Microscopy 
SEM provided a technique to observe changes in the architecture of the 
material after decellularization and crosslinking.  It also allowed for the important 
step of ensuring the AuNPs were present after sterilization of the tissue.  Our 
results demonstrated that the 20 nm AuNPs did not survive the sterilization 
process.  Most likely the peracetic acid and low pH used in the study disrupted 
the atomic bonding causing the dissipation of the atoms. Other studies have also 
shown problems with sterilization of small nanoparticles [31, 32].  While we 
discovered that the 20nm AuNPs could not survive, we could identify the 100nm 
AuNPs using EDS.  Thus 100 nm AuNPs were utilized for the biocompatibility 
study instead of the 20 nm AuNPs.  Additionally, several recent studies have 
indicated concerns with cytotoxicity of AuNPs at very small sizes (<20nm); we 
concluded that using larger nanoparticles, i.e., 100nm AuNPs would be more 
conducive to the design of vascular patches [32, 33].  In other studies, the 100 
nm AuNPs have shown positive biocompatibility and free radical scavenging 
effects without cytotoxity concerns [22, 34, 35].   
 
4.5.4 Mechanical Testing 
The loss of native mechanical properties of decellularize tissue will negate 
the usefulness of the scaffold as a vascular repair material [36].  While previous 
studies have shown conflicting results regarding methods of decellularization 
decreasing mechanical strength [23, 37-39], we found no significant differences 
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between the native arteries, the decellularized arteries, crosslinked arteries, and 
AuNP arteries.  Sterilization of the scaffolds also did not change the mechanical 
properties significantly from that of the native vessels.  Our modifications did not 
have adverse effects on the mechanical properties; this is very important when 
considering problems such as intimal hyperplasia which may be caused when 
compliance mismatch occurs between the native vessel and the patch material.     
 
4.5.6 Biocompatibility 
There have been conflicting studies on the cytotoxicity of gold 
nanoparticles; however, many studies do agree that size plays an important role 
in cytotoxicity.  Our lab has previously tested the effects of varying 
concentrations of AuNPs on cytotoxicity and noted that specimens crosslinked 
with AuNPs at 4x the stock solution showed the same levels of cell growth as 
specimens without AuNPs [40].  Therefore we chose to use a concentration of 4x 
to avoid wastefully repeating past experiments.  The 100 nm AuNPs used in this 
study were conjugated to tissue and the WST-1 assay was utilized to test the 
biocompatibility of the material, which showed no cytotoxic effects with human 
umbilical endothelial cells.  The decellularized, crosslinked, and crosslinked with 
AuNPs showed equivalent cellular viability.  The 100nm AuNPs at 4 times the 
stock concentration showed no cytotoxic effects.  This assay suggests that the 
100nm AuNPs are biocompatible.   
 
84 
 
4.5.7 Cell Proliferation 
Previous studies have demonstrated that the presence of AuNPs will 
increase cell proliferation [17, 18, 29].   The rough topography of scaffolds with 
nanoparticles provides attachment sites for adhesion-loving cells, such as 
fibroblasts.  Additionally, the high surface energy of nanoparticles may also be 
attracting cells.  Cell proliferation was quantified using a dsDNA assay.  The 
assay showed no significant differences between groups at each time point.  
However the cells did continue to proliferate over time rather than dying off.  
Again, there is no cytotoxicity seen with the use of the AuNPs.  The lack of 
increased proliferation shown in the study may be due to the different cell line.  
Typically, mouse fibroblast cells were utilized in our previous studies and many of 
the studies cited in literature.  The use of the endothelial cell line could indicate 
that endothelial cells are not attracted to high surface energies materials and/or 
roughened surfaces. 
 
4.6 Conclusions  
This study characterized decellularized porcine aortic tissue conjugated to 
amine functionalized gold nanoparticles.  The purpose of this study was to 
characterize and test the feasibility of a novel decellularized vascular patch that 
had been conjugated with AuNPs.  It was hypothesized that AuNP-conjugated 
blood vessels would help maintain the natural tissue properties such as strength, 
stiffness, and open microstructure while providing good biocompatibility.  The 
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results supported the hypothesis.  The decellularization process removed all 
immunogenic material from the patch, and the decellularization and crosslinking 
processes did not change the mechanical properties of the native vessel.  In 
addition it was demonstrated that crosslinking and conjugation of AuNPs did not 
cause significantly alter endothelial cell growth.  This material has the potential to 
be a feasible vascular patch.   
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  Chapter Five 
AN IN VIVO STUDY OF THE EFFECTS OF A 
NANOMATERIAL-TISSUE PATCH FOR VASCULAR AND 
CARDIAC RECONSTRUCTION IN A PORCINE MODEL 
5.1 Abstract 
  Vascular and cardiac reconstruction involves the use of biological patches 
to treat trauma and defects. An in vivo study was performed to determine the 
remodeling and biologic effects of novel nanostructured vascular patches with 
and without gold nanoparticles.  Porcine vascular tissue was decellularized and 
conjugated with gold nanoparticles to evaluate if integration would occur while 
avoiding rupture and stenosis.  Swine underwent a bilateral patch angioplasty of 
the carotid arteries with experimental patches on the right and control patches of 
bovine pericardium on the left.  Animals were sacrificed after surgery and at 3 
and 9 weeks.  Ultrasound was performed during surgery, every 3 weeks, and 
before euthanasia.  Endothelial regeneration was examined using Evans Blue 
dye and histology using Trichrome and H&E. There was a 100% success rate of 
implantation with 0% mortality.  All patches were patent on ultrasound.  At 3 
weeks, experimental patches had regenerating endothelial cell growth and 
normal healing responses. At 9 weeks, the experimental patches demonstrated 
excellent integration, particularly the gold nanoparticle carotid vascular patch.  
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Histology demonstrated cellular in-growth into the experimental patches and no 
major immune reactions.  This is one of the first studies to demonstrate the 
feasibility of nanomaterial-tissue patches for vascular and cardiac reconstruction.  
 
5.2 Introduction 
Cardiac and vascular materials are utilized to treat trauma and 
aneurysms, repair congenital defects, and patch defects in vessel and cardiac 
walls [1-4].  Finding a suitable material for these repairs has included research in 
both biologic and synthetic materials [1, 5].  The ideal material must mimic the 
mechanics and biocompatibility of the natural tissue as close as possible [6-11].  
Current synthetic and biologic scaffolds can cause negative host reactions such 
as inflammation, calcification, and infection [12-17].   
 Synthetic materials such as expanded polytetrafluoroethylene (ePTFE) and 
Dacron (polyethylene terephthalate) possess good mechanical properties and 
have demonstrated acceptable in vivo durability.  However synthetic materials 
can cause a foreign body response leading to chronic phase inflammation and 
thrombus formation and are often unable to promote endothelial cell migration 
and remodeling [18].  They often have poor flow hemodynamics and are unable 
to “grow”, which is especially problematic with pediatric patients.  When used as 
small diameter vascular grafts they have a high rate of thrombosis and do not 
maintain long term patency [19, 20].  
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Biological materials, such as swine small intestine submucosa (SIS), are an 
alternative to synthetic materials.  In a vascular environment, biologic materials 
tend towards mechanical failure, re-stenosis, and calcification [18].  In particular 
the use of glutaraldehyde crosslinkers to stabilize biologics has been shown to 
promote calcification as well as display cytotoxic effects upon degradation.  The 
biologic materials do not have the durability of the synthetics. An ideal biologic 
would possess a natural three-dimensional tissue structure that would enhance 
remodeling while providing mechanical strength.   
We have been investigating a biologic construct that possesses a natural 3D 
tissue structure while being conjugated with gold nanoparticles (AuNPs).  The 
conjugation of AuNPs to biological constructs has been shown to improve the 
overall biocompatibility performance of the constructs [21, 22]. The conjugation 
method can increase the stability of the tissue due to the AuNPs hindering 
collagenase binding sites [21].  This can help prevent early degradation of the 
material, giving the body time to properly infiltrate and remodel the tissue.  
Studies have also shown that the addition of AuNPs can improve the thermal and 
mechanical properties of material [22]. 
A preliminary pilot study was performed in order to acquire early evidence 
that the use of decellularized porcine arteries conjugated with nanomaterials 
could be utilized as a possible patch material in vivo.  It was hypothesized that 
the arteries conjugated with AuNPs would show enhanced cellular integration 
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and remodeling when compared to the currently used non-autologous patch 
material while also avoiding stenosis.   
 
5.3 Materials and Methods 
5.3.1 Materials 
Unconjugated gold nanoparticles (100nm diameter, 5.6x109 particles/ml) 
were purchased from Ted Pella, Inc. (Redding, CA)  Trypsin EDTA, Dulbecco’s 
phosphate buffered saline, Eagle’s Minimum Essential Medium, horse serum, 
were obtained from ATCC (Manassas, VA).  Triton X-100, peracetic acid 
(99.5%), 2-mercaptoethylamine (MEA), 1-Ethyl-3-[3-
dimethylaminopropyl]carbodiimide hydrochloride (EDC), and phosphate buffered 
saline were acquired from Sigma-Aldrich (St. Louis, MO).  
Nydroxysulfosuccinimide (Sulfo-NHS) was obtained via Pierce, a part of Thermo 
Fisher Scientific in Rockor, IL.  Acetone (99.5%) and formalin (10% buffered) 
came from Thermo Fisher Scientific (Fair Lawn, NJ).  The control bovine 
pericardium patch was a Peri-Guard Repair Patch® from Synovis (St. Paul, MN).   
 
5.3.2 Study Design 
The study design involved the use of four different types of experimental patches:   
1) Decellularized porcine abdominal aorta blood vessel patch (DBVP);   
2) Decellularized and crosslinked porcine abdominal aorta blood vessel patch 
(CBVP);  
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3) Decellularized and crosslinked with 100nm gold nanoparticles attached to 
porcine abdominal aorta blood vessel (GBVP); 
4) Decellularized and crosslinked porcine carotid artery patch with 100nm 
gold nanoparticles (GCVP) – (for the 9 week time point only). 
The study was designed with a feasibility “acute study” component where the 
patches were implanted in three non-survival porcine models. For the 3 and 9 
week study, the survival component comprised a total of 11 animals. The three-
week time point had 3 animals - one for each type of experimental patches 1) 
through 3). The nine week time point had a total of 8 animals- two for each type 
of experimental patch groups from 1) through 4).  Table 5.1 displays the 
experimental groups.  Each animal was its own control, receiving a commercially 
available bovine pericardial patch on the contralateral artery.  
 
Table 5.1 Experimental groups and time points 
 
*This was a single animal with AuNP aorta implant on the right side and the 
AuNP carotid on the left. 
 
 
 
 Total 
Animals 
Decellularized 
Aorta (DBVP) 
Cross-linked 
Aorta(CBVP) 
AuNP 
Aorta 
(GBVP) 
AuNP 
Carotid 
(GCVP) 
Acute 
Study 
3 1 1 1* 1* 
Three 
Week 
3 1 1 1 0 
Nine 
Week 
8 2 2 2 2 
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5.3.3 Tissue Harvest and Decellularization 
 Porcine aortas and carotids were harvested immediately following 
euthanasia of swine after a laboratory exercise at the University of Missouri 
School of Medicine.  Decellularization was performed using a protocol adapted 
from a previously published protocol [23, 24]. 
   
5.3.4 Crosslinking 
As shown in Table 1, three of the four experimental groups were 
crosslinked.  A crosslinking solution (50:50 (v/v) solution of acetone and PBS 
with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) and N-
hydroxysuccinimide(NHS) was prepared and the decellularized tissue was 
incubated in this solution for 15 minutes at ambient temperature.  After the 
incubation the crosslinking solution was withdrawn and functionalized AuNPs 
(100 nm in diameter) were added to allow peptide binding to the tissue.  The gold 
nanoparticles were functionalized using a solution of 2-mercaptoethylamine.  The 
crosslinked tissue group remained in the crosslinking solution (experimental 
group 1).  After processing, all types of the experimental tissue were incubated 
for 24 hours at ambient temperature with gentle agitation followed by two 24 
hours rinses with PBS.   
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5.3.5 Sterilization 
 Specimens were incubated in an aqueous solution of 0.1%(v/v) peracetic 
acid with 1.0M NaCl for 30 minutes followed by two 24 hour sterile PBS rinses.  
All steps were performed at ambient temperature with shaking.  Completed patch 
material can be seen in Figure 5.1.   
 
5.3.6 Animals 
Female domestic swine with a starting weight of approximately 120 lbs 
were singly housed in accordance with the NIH guidelines for the care and use of 
laboratory animals (NIH Publication #85-23 Rev. 1985) and were observed under 
a protocol approved by the Institutional Animal Care and Use Committee.  On the 
day preceding surgery animals were given 325 mg aspirin orally.  Intramuscular 
(IM) telazol (4.4-6.6 mg/kg body weight), xylazine (2.2 mg/kg) and atropine (0.05 
mg/kg) was given as a preanesthetic.  2-4% Isoflurane was administered via 
nose cone until the animal was sedated enough to be safely intubated.  A 
surgical plane of anesthesia was maintained using 1-3% isoflurane gas and a 
ventilator at 6-8 breaths/minute.  Prior to the surgical incision animals were given 
ceftiofur (5 mg/kg IM).  An intravenous (IV) catheter was placed in the ear with an 
isotonic sodium chloride flow throughout surgery.  Heparin was given IV at an 
initial bolus of 10,000 U/kg followed by 5,000 u/kg every hour intra op when 
necessary.  Post operatively the animals were given carprofen (3mg/kg) 
subcutaneously (SQ) and buprenorphine (0.01-0.02 mg/kg) IM.  The 
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buprenorphine dose was repeated at 6-8 hours after the animal was sternal.  
Animals received 325 mg aspirin PO for 3 days post op and then 81 mg/day PO 
until sacrifice.   
At the conclusion of the study the animals were anesthetized as previously 
described.  Three and nine week animals were given Evan Blue Dye at 2ml/kg of 
a 2% solution IV which was allowed to circulate for 30 minutes.  The carotid 
arteries were ligated and excised before the animals were sacrificed using 
pentobarbital sodium and phenytoin sodium (Beuthanasia - 1 ml/4.5 kg IV).   
 
5.3.7 Operative Procedure 
All animals underwent a bilateral carotid patch angioplasty.  Sterile 
technique was used throughout.  A midline incision was made over the trachea 
and the carotid arteries were exposed.  Each artery was dissected out and 
proximal/distal control was obtained using vessel loops.  A longitudinal 
arteriotomy 2 cm long was created and patches were implanted over the 
arteriotomy using 6-0 prolene continuous running suture technique (Figure 5.1a).  
The experimental patch was placed on the right side (Figure 5.1b) and the 
control patch on the left in each animal.  The muscle and the subcutaneous 
layers were opposed using Vicryl in a simple continuous pattern, the skin was 
closed with a continuous intradermal suture pattern using absorbable suture.   
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Figure 5.1 Intro-op placement of the patches  
 
a) 2 cm longitudinal defect created on the carotid artery after the occlusion of the 
artery using vessel loops 
 
b) GBVP patch sutured onto the defect in the artery, showing typical patch 
placement 
 
5.3.8 Ultrasound 
Doppler ultrasound (LS probe on a Logique GE ultrasound) was used to 
visualize the flow through the arteries.  During the initial surgery the vessels were 
imaged before the arteriotomy as a baseline and then following patch placement.  
Nine week animals were sedated at three and six weeks post-op using IM telazol 
(4.4-6.6 mg/kg body weight), and xylazine (2.2 mg/kg) for percutaneous 
ultrasounds.  A final reading was taken before sacrifice.   In the 9 week animals 
color flow as well as waveform characteristics were imaged.  The velocity and 
diameter of the vessels was recorded before the arteriotomy and at each time 
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point.  The percentage area stenosis was calculated using the following equation 
which has been used in previous publications [25]: 
(1-[D2× D2×V2]/ [D0× D0×V1]) × 100% 
Where D0 is the diameter of the vessel at the patch at the time of euthanasia and 
D2 is the diameter of the vessel before patch placement (reference area).  V1is 
the peak velocity at the time of euthanasia and V2 is the peak velocity at the 
reference area as can be seen in Figure 5.2. 
   
 
Figure 5.2 Ultrasound image of the GCVP at 9 weeks showing the pulsatile flow 
through the artery as well as the measurement of the systolic and diastolic flow 
rates.  There was no vessel occlusion seen on any of the arteries at any time 
point.  The flow rates were analyzed and there was no significant difference 
between control and experimental patches.  
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5.3.9 Gross Examination 
After explantation each artery was photographed (Canon PowerShot 
A4000 IS) and then incised longitudinally opposite to the patch site.  After 
exposure the level of blue staining was photographed.  Each sample was cut in 
half and stored in 10% formalin for at least 24 hours or 70% ethanol.  In all 
survival animals, the patches were grossly examined for bowing of the patches, 
Evan’s Blue staining, thickening of the blood vessel wall, and fibrinous debris.  
Only fibrinous debris was examined in the non-survival animals. 
 
5.3.10 Histology 
Longitudinal and cross sectional samples were embedded in paraffin, cut 
with a microtome at 5 µm and stained with hematoxylin and eosin (H&E) for all 
studies and also with a Masson’s trichrome stain for all survival studies.  All 
slides were viewed at 50x, 100x, 200x, and 400x.  Viewing was performed on a 
Zeiss Axiophot (Carl Zeiss Microimaging, Inc., Thornwood, NY) and photographs 
were acquired using an Olympus DP70 (Olympus America Inc., Center Valley, 
PA) camera with DP Manager Version 1.21.107 as the acquisition software. 
 
5.3.11 Statistical Analysis 
GraphPad Prism v4.0 (GraphPad Software, Inc., San Diego, CA) was 
used to analyze experimental data. One-way analysis of variance (ANOVA) with 
a 95% confidence interval was conducted followed by a Tukey-Kramer post-test 
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to determine significant differences between means of the experimental groups 
and control for the percentage of stenosis.   
 
5.4 Results  
5.4.1 Non-Survival Observations 
The results of the non-survival, acute study demonstrated that there would 
be no catastrophic failure with the patch material.  It also allowed for refinement 
of the surgical approach and indicated the size of the swine being used were 
acceptable substitutes for human subjects.  It also allowed the surgeon to 
differentiate between the four experimental groups used in terms of material 
handling and suturing.  The anesthetic and ultrasound techniques used for this 
particular procedure proved to be sound.  No arteries were ligated for more than 
30 minutes.    
 
5.4.2 Gross Examination Results  
For the non-survival acute animals red fibrinous debris was noted on the 
luminal side of the patches in all patches.  There was a slight increase in the 
amount of fibrinous debris on the control patch for the second animal with the 
CBVP (experimental group 2), but this debris did not hinder blood flow as noted 
by the ultrasound. 
In all survival animals, the patches were grossly examined for bowing of 
the patches, Evan’s Blue staining, thickening of the blood vessel wall, and 
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fibrinous debris.  In all the survival animals, both arteries demonstrated slight 
bowing in the area of patch placement, but this bowing did not hinder blood flow 
as noted by the ultrasound.  Table 5.2 provides a summary of the 3-week gross 
examination results.  The 3 week results demonstrated that there was a variety of 
changes.  For example, Evan’s Blue staining was noted as minimal to moderate 
amounts on all vessels.  Thickened vessel walls were noted in some groups and 
not others.   
Table 5.3 summarizes the results of the 9 week animals.  Grossly the control 
patches were not well integrated in any of the animals.  For the experimental 
patches, the GCVP (gold nanoparticle carotid patch, group 4) showed the best 
gross integration.  There was variable Evans Blue dye staining of both control 
and experimental patches.  No major clots were noted inside the vessels.  Figure 
5.3 displays the gross images of the explanted patches and vessels.   
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Figure 5.3 Gross images taken at the time of patch explantation  
 
a) GBVP at nine weeks showing the gross integration of the tissue patch into the 
vessel.   
 
b) GCVP at nine weeks showing the presence of the suture along the patch 
outline, but overall excellent gross integration of the patch 
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Table 5.2 Summary of 3 week gross examination results 
 
 
Table 5.3: Summary of 9 week gross examination results 
 DBVP Control CBVP Control GBVP Control CBVP         Control 
Evans 
Blue 
Staining 
Minimal  Minimal Minimal 
Moderat
e 
Minimal Minimal Minimal Minimal 
Host 
integration Moderat
e 
Poor 
Moderat
e 
Poor 
Moderat
e 
Poor  
Excellen
t 
Poor 
Other 
features 
No No No 
Increase
d 
bowing 
of artery 
Some 
scarring 
Yellowe
d patch 
No 
Yellowe
d patch 
 
 
 
 
5.4.3 Histologic Assessment Results 
In the acute study there were no major histologic changes seen on the 
H&E slides.  Both experimental and control patches were evident.  The DBVP, 
CBVP, and GBVP patches were all close to the same thickness as the control 
 DBVP Control CBVP Control GBVP Control 
Evans Blue 
Staining 
Minimal Minimal Moderate Moderate Moderate Moderate 
Integrated 
with host  
Moderate Poor Moderate Poor Poor Poor  
Other 
features 
No No No 
Clotted 
blood, 
thickened 
vessel wall 
Small 
mass, 
thickened 
vessel 
wall 
Opaque, 
yellow 
crystals, 
clotted 
blood, 
thickened 
vessel wall 
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patch; between 800-1000 µm.  The GCVP was thinner than the others (400 µm) 
and showed an infiltration of red blood cells between the collagen fibers. 
Both H&E and trichrome staining were performed on the survival study 
patches.  The results of the trichrome slides are shown in Figures 5.4-5.6.  The 
trichrome stains highlight the collagen fibers of the patch materials better than 
the H&E stains.   
As shown in Figure 5.4a and 5.5a, in the three-week animals the control 
patches were a very bright blue on the trichrome slides and showed thick wavy 
collagen fibers.  The experimental patches have thin strands that stained lightly 
basophilic.  Both patches of the DBVP (group 1) animal had inflammation.  The 
control side (group 1) showed lymphocytes and multinucleated cells and a mild 
infiltration of cells into the patch.  The experimental sides showed lymphocytes 
and fibroblasts, with cells penetrating further into the patch.   
The CBVP (group 2) demonstrated an increased cellular layer within the 
lumen of the vessel, more inflammatory cells, and not as much cellular infiltration 
into the patch as the DBVP (group 1) as shown in Figure 5.4 and 5.5b,c.  The 
control on this animal (group 2) had a blood clot adhered to the luminal surface.   
The results of the GBVP (group 3) histology demonstrated a mass (seen 
grossly) which appeared to be an organized thrombus.  Part of the thrombus is 
encapsulated with fibroblasts and contains debris, red blood cells, and 
hemosiderin.  The area cut in without the mass has moderate cellular infiltration 
and inflammation as shown in Figure 5.4d and 5.5d.  The control side (group 3) 
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showed a large inflammatory response and moderate occlusion of the vessel 
lumen.  Both the CBVP (group 2) and the GBVP (group 3) showed mononuclear 
cellular infiltration into the scaffolds with some higher concentrations of 
inflammatory cells at the edges of the patches.  The control patches (group 3) 
also showed cluster of lymphocytes and minimal cellular infiltration.  The second 
GCVP (group 3) had cells growing into the scaffold, indicating infiltration.  Areas 
of the scaffold were difficult to discern from the native structure.  The control side 
(group 3) showed minimal cellular infiltration.  See Table 5.4 for summarized 
results.  
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Figure 5.4 Histologic images of patches explanted at three weeks, trichrome 
staining, at 5x with representative control.  The bar indicates 1mm.   
 
a) The control patch is very obvious as the deeply blue stained area (arrow), 
indicating the distinct junction between the native tissue and control patch 
 
b) DBVP at three weeks where the arrow indicates the experimental patch with 
the less distinct junction.  There are red blood cells and other cells within the 
layers of the patch material 
d) CBVP at three weeks again showing the junction between patch and native 
tissue with cells infiltrating the patch.   
 
d) GBVP at three weeks with the arrow highlighting the cells infiltrating the patch.  
The amount of patch material present is thinner as this is the carotid patch.   
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Figure 5.5 Histologic images of patches explanted at three weeks with trichrome 
staining at 20x with representative control 
 
a) The control patch has a very distinct junction (arrow) with the native tissue and 
very minimal cellular infiltration  
 
b) DBVP at three weeks showing a less distinct junction between host and patch 
with infiltration by red blood cells (arrow) 
 
c) CBVP at three weeks showing the junction between patch and native tissue 
with cells (arrow) infiltrating the patch.   
 
d) GBVP at three weeks with the arrow highlighting the cells infiltrating the patch.   
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Table 5.4 Summary of 3 week histology results 
 
 
At nine weeks the animals with the DBVP (group 1) showed significant 
cellular infiltration of mononuclear and RBCs into the scaffold material.  There 
were also mononuclear cells lining the lumen of the vessel and an inflammatory 
response as shown in Figure 5.6a.  The controls (group 1) showed very mild 
cellular infiltration and inflammatory cells could be seen along the anastomosis 
sites.  One of the CBVP (group 2) animals had a significant immune response 
with dense areas of lymphocytes on the edges of the patch, infiltrating the patch 
as demonstrated in Figure 5.6b.  The control on this animal also showed 
organized lymphocytes and a thick layer of fibrous tissue on the luminal side.  
The other CBVP animal (group 2) showed cellular infiltration of the scaffold with 
mononuclear cells and lymphocytes present on the periphery of the scaffold.  
The GBVP (group 3) had cells lining the lumen of the vessel as well as 
penetrating the patch and was very close to the smooth muscle cells as shown in 
Figure 6C.  The animal with the GCVP (group 4) that had post-operative 
problems showed very few cells infiltrating the control or experimental patches, 
 DBVP Control CBVP Control GBVP Control 
Cellular 
infiltration/ 
host 
integration 
Moderate Mild Mild Mild Moderate Moderate 
Inflammatory 
reaction  
Mild Mild Moderate Moderate Moderate Mild  
Thrombus 
formation 
No No No Blood clot 
Organized 
thrombus 
Moderate 
occlusion 
of the 
vessel 
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with both also having lymphocytes present and numerous red blood cells.  The 
second GCVP animal (group 4) demonstrated infiltration of blue connective 
tissue (on the trichrome stain) into the patch, which was at times difficult to 
discern from the native tissue (Figure 5.6d).   See Table 5.5 for summarized 
results. 
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Figure 5.6 Histologic images of patches explanted at nine weeks with trichrome 
staining at 5x  
 
a) DBVP at nine weeks with the arrow indicating native cells deep within the 
patch material 
 
b) CBVP at nine weeks showing how the matrix of the patch has expanded to 
allow for host infiltration with the arrow noting the immune response to the patch 
(also present on the control side in this animal) 
 
c) GBVP at nine weeks had cells lining the lumen of the vessel (arrow) as well as 
penetrating the patch and was very close to the smooth muscle cells 
 
d) GCVP at nine weeks demonstrating infiltration of blue connective tissue 
(arrow) into the patch, which was at times difficult to discern from the native 
tissue 
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Table 5.5 Summary of 9 week histology results  
 DBVP Control CBVP Control GBVP Control CBVP         Control 
Cellular 
infiltration/ 
host 
integration 
Significant  Mild Moderate Mild Significant Mild Significant Mild 
Inflammatory 
reaction  
Mild Moderate Mild Moderate Mild Mild  Mild Moderate 
Thrombus 
formation 
No No No No No No No No 
 
5.4.4 Ultrasound Results 
The results of the ultrasound data showed no pre-existing conditions in the 
carotid arteries of any of the animals. In the three week animals, all arteries were 
patent after patch placement and at sacrifice.  Gross examination of the lumen of 
the arteries showed varying degrees of stenosis in several of these animals, as is 
discussed in the gross results section, though blood flow was noted through all. 
In the nine week animals, all arteries were patent at all time points.  The 
pulsatile waveform of the GCVP patch at nine weeks is shown in Figure 5.2.  The 
diameters and velocities of the vessels were used to compute the percentage of 
stenosis as described above.  There were no significant differences in 
percentage of stenosis area between the control and experimental patches at the 
time of euthanasia. 
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5.5 Discussion 
This study investigated the remodeling characteristics and biologic effects 
of different patch materials including a novel design which incorporated AuNPs 
into a decellularized blood vessel. The goal of the study was to determine how a 
novel nanomaterial-tissue construct design would behave in vivo when compared 
to a commercially available biologic patch.  Parameters that were measured 
included rupture, stenosis, endothelial cell regeneration, and cellular infiltration in 
a swine cardiovascular model.  Vascular repair materials must closely mimic the 
native tissue structure that is being replaced in order to avoid intimal hyperplasia 
(occlusion) and rupture.  The use of decellularized blood vessels is 
advantageous because its mechanical advantage and its ability to retain 
structural elements, which can include stimulating growth factors that can support 
cell growth and differentiation [21, 26-29].  Additionally, conjugation of AuNPs to 
the constructs is also advantageous because AuNPs have been shown to 
increase stability, decrease inflammation, and slow down scaffold degradation 
[21, 26-29].  The results of this pilot study demonstrated that the novel AuNP-
blood vessel material is biocompatible in a vascular environment; the patches 
presented increased tissue integration when compared to the control bovine 
pericardium material.   
The use of arterial tissue as a vascular repair material yields a patch with 
characteristics very similar to that of the native tissue.  The initial acute 
procedures showed that the patch could be easily handled in surgery and had 
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acceptable suture holding strength.  The 100% success rate of implantation and 
0% mortality rate demonstrated the ability of the material to be utilized as a 
vascular substitute in vivo.  It is able to withstand the pressures and responses 
that occur with implantation of a vascular patch material.  Nine weeks after 
implantation, all the experimental patches showed cellular ingrowth and the 
thinnest patch, the GCVP, demonstrated exceptional integration with the lumen 
of the vessel.  It is possible that the addition of the gold nanoparticles as well as 
the thinner graft material enhanced cellular adhesion and migration.  The 
dimensions of the thinner patch may be more conducive to remodeling because 
of the shorter migration distance of the host cells into the graft material, and thus 
allow for more host cells to infiltrate and vascularize the patch.  It is also possible 
that the high surface energy of the AuNPs attracts cells and thus increased 
cellular migration and adhesion.  These differences may lead to faster, enhanced 
cellular remodeling, and thus the improved integration.   
The ultrasound data demonstrated that there were no initial problems 
within the vessels and that they remained patent throughout the experiment.  The 
calculated percent stenosis of the vessels varied widely.  Since the animals must 
be sedated during the ultrasound measurements, the blood velocity readings 
may not accurately reflect the flow of the blood pass the patches.  The changes 
in velocity could be caused by inappropriate angle alignment or by the inherent 
nature of the tortuous vessels [29].   
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The gross examination of the vessels and the Evans Blue staining 
indicated that there was endothelial cell growth on the patch areas within the 
lumen.  These events were not as evident in the nine week animals, which may 
indicate that the endothelial cells were no longer taking up the dye, an indication 
of mature cells, rather than regenerating ones since only regenerating cells will 
uptake the dye.  The difficulty in grossly discerning the GCVP (group 4) from the 
native tissue at the nine week time point demonstrates excellent integration with 
the native tissue.  The patch remained in place while allowing the native tissue to 
grow into and integrate with the scaffold.   
The histology slides cut from this study demonstrated differences between 
the control and the experimental patches.  At a microscopic level, the control and 
experimental patches have different widths of collagen strands and differences in 
the structure, as the control patch collagen strands tend to be thicker and closer 
packed than the decellularized arterial tissue.  These differences can be noted by 
the different hues of blue found on the trichrome stained slides.  Structural 
differences occur due to the different types of tissue being used and possibly 
from the crosslinking.  The bovine pericardium control patch material has a 
different collagen orientation than the experimental blood vessel patches.  
Additionally, the bovine patch was crosslinked with glutaraldehyde. 
The experimental patches are crosslinked in order to conjugate the AuNPs 
to the material.  Crosslinking is typically performed in order to improve 
mechanical properties of acellular scaffolds; however, crosslinking has been 
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shown to adversely affect biocompatibility, leading to fibrous encapsulation.   To 
avoid possible adverse biocompatibility issues but still achieving a structurally 
stable scaffold, we lightly crosslinked (using low molarity) the AuNPs to the 
acellular scaffold using  a zero-length crosslinker, EDC, which has also been 
shown to be more cell friendly.  Conjugating AuNPs to acellular scaffolds as well 
as to purified collagen has been shown to hinders collagenase binding sites;[21] 
therefore, less crosslinking is needed to achieve long term stability and thus less 
changes in the natural tissue structure [30].  The histology results supported the 
concept of increased stability and equivalent mechanical properties when the 
crosslinked patches are compared to the control material.   
 
5.6 Conclusions 
This was one of the first studies to demonstrate the feasibility of a vascular 
nano-material biological patch.  The survival of all animals indicated that the 
patch material is compatible with a vascular environment and is capable of 
withstanding the mechanical forces while also enhancing cellular integration and 
avoiding stenosis.  While the results were very encouraging it is noted that the 
study was a pilot study; the number of animals used was low and the time points 
were short.  The material will be further explored with long term animal studies, 
as well as with other applications such as aortic patching.    
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Chapter Six 
AN IN VIVO STUDY OF A NOVEL GOLD 
NANOCOMPOSITE BIOMATERIAL FOR VASCULAR 
REPAIR 
6.1 Abstract 
Currently vascular repairs are treated using synthetic or biologic patches, 
however these patches have an array of complications, including calcification, 
rupture, re-stenosis, and intimal hyperplasia.  A more effective patch material 
composed of decellulzarized tissue conjugated to gold nanoparticles (AuNPs) 
was developed and the long term biocompatibility and cellular integration was 
investigated.  Porcine abdominal aortic tissue was decellularized and crosslinked 
with 100nm gold nanoparticles (AuNP).  These patches were placed over a 
longitudinal arteriotomy of the thoracic aorta in six pigs.  The animals were 
monitored for six months.  Gross, histological, and immunohistochemical 
analyses of the patches were performed after euthanasia.  Grossly there was 
minimal scar tissue with the patches still visible on the outer surface of the 
vessel.  The inner lumen was smooth and went from patch to native tissue 
seamlessly.  Histologically there was infiltration of host cells into the patch 
material.  The immunohistochemical results showed that an endothelial cell layer 
had formed over the patch within the vessel and smooth muscle cells were 
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repopulating the biomaterial in all animals.  These results demonstrated that the 
AuNP biomaterial had excellent in vivo feasibility.  It integrated well with the host 
tissue and was not rejected nor failed over the six month period of time.  The 
host cells re-populate the biomaterial’s matrix appropriately and with minimal 
immune response.  This biomaterial holds great promise as a vascular repair 
material.   
 
6.2 Introduction 
Vascular patch materials are used to repair and reconstruct damage to 
blood vessels [1-3].  These patch materials ideally mimic the native extracellular 
matrix, sustain and guide new cell growth, avoid intimal hyperplasia, resist 
infection, and degrade after new tissue has formed [4-9].  Unfortunately an ideal 
material has not yet been created, and currently a variety of synthetic and 
biologic materials are in use [10, 11].  The currently used synthetic and biological 
materials can cause immune reactions, infections, calcification, and neo-intimal 
hyperplasia [3, 12-16].   
Synthetic materials such as expanded polytetrafluoroethylene are strong 
and long lasting in vivo.  However they are susceptible to thrombus formation, 
calcification, and infection [17].  The native tissue tends to have a strong foreign 
body response to these types of materials and this leads to chronic inflammation.  
The cells have difficulty integrating into these synthetic materials which in turn 
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leads to their inability to continue growing when used in pediatric patients [18].  
Biologic materials such as bovine pericardium better approximate characteristics 
of the native tissue than synthetic materials, but tend to be weaker and degrade 
quicker in the body [19, 20].  Both types of materials show foreign body 
responses, intimal hyperplasia and increased thrombogenicity when compared to 
native tissue [21, 22].   
To counter these problems new types of materials and surface modifications 
are being explored.  One of these surface modifications is the use of gold 
nanoparticles (AuNPs).  AuNPs are biologically inert and can increase 
antimicrobial properties of biomaterials while also aiding cell proliferation [23-27].  
They are being investigated in numerous medical applications such as drug 
delivery, imaging, biosensors, diagnostics, gene therapy, and nanocomposite 
biomaterials due to their biocompatibility, optical properties, and conjugation 
capabilities [28-33].  AuNPs have been shown to improve the thermal and 
mechanical properties of material and hinder collagenase binding sites to create 
a more stable biomaterial sites [23, 34].  This is extremely important in tissue 
engineering that require constructive remodeling  
 In this study, we developed a nanocomposite vascular patch using gold 
nanoparticles and decellularized arterial tissue matrices.  Our objective was to 
perform a long term in vivo test of our biomaterial.  The hypothesis for this 
experiment was that the novel nanocomposite biomaterial would show minimal 
immune response, endothelial and smooth muscle cell regeneration, and overall 
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excellent integration and biocompatibility with the host tissue.  Gold nanoparticles 
were conjugated onto the decellularized tissue and implanted on the thoracic 
aorta of swine.  Six months after implantation, wound healing, tissue remodeling, 
endothelial cell regeneration, and cellular integration were investigated by gross, 
histological, immunohistochemical, and electron microscopic analyses.   
 
6.3. Materials and methods 
6.3.1 Tissue Harvest and Decellularization 
Decellularization was performed following a previously published protocol 
[35, 36].  Porcine abdominal aortas were harvested immediately following 
euthanasia of swine at the University of Missouri.  Blood and any excess 
connective tissue were removed and then they were immersed in distilled water 
for 24 hours at 4° C.  The vessels were treated with 0.025% trypsin EDTA 
(ATCC) diluted in Dulbecco’s phosphate buffered saline (dPBS; ATCC) for 24 
hours at 37 °C.  The tissue was decellularized with a solution of 1% Triton x-100 
(Sigma) and 0.1% ammonium hydroxide (Fisher) in distilled water for 72 hours at 
4 °C.  It was then washed in a solution of Eagle’s Minimum Essential Medium 
(EMEM; ATCC) 10% (v/v) horse serum and PennStrep (200 U/mL).  The material 
was immersed for 24 hours in distilled water at 4 °C and then for 48 hours in PBS 
at 4 °C, changing the PBS to fresh solution at 24 hours.  All of these steps were 
done with agitation.   
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6.3.2 Crosslinking 
  Decellularized patches were incubated for 15 minutes at ambient 
temperature in a crosslinking solution (50:50 (v/v) solution of acetone and PBS 
with 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) and N-
hydroxysuccinimide(NHS).  100 nm AuNPs at 4 times the stock solution were 
functionalized using a solution of 2-mercaptoethylamine and added to the tissue.    
The patches were incubated for 24 hours at ambient temperature with gentle 
agitation followed by two 24 hour PBS rinses.  Sterilization occurred via 
immersion in an aqueous solution of 0.1%(v/v) peracetic acid with 1.0M NaCl for 
30 minutes followed by two 24 hour sterile PBS rinses at ambient temperature 
with shaking.  
 
6.3.3 Suture Pullout Testing 
 Suture pullout testing was performed on native porcine aortic tissue (n=5), 
decellularized porcine aortic tissue (n=7), crosslinked porcine aortic tissue (n=9), 
and bovine pericardium (n=5).  The bovine pericardium was chosen to represent 
the typical biologic repair patch that would be used in human medicine.  As noted 
in Chapter 3 the addition of AuNPs did not significantly change the mechanical 
properties of the material, so they were not retested here.  Each piece of tissue 
was cut into a 10mm x 10mm strip.  A piece of 6-0 prolene suture that is typically 
used for this type of procedure in vivo was tied 3mm from one edge to create a 
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5mm loop.  The tissue was gripped with a pneumatic grip set to 52psi, and the 
suture was placed over an opposing hook.  An Instron TA.XT2 mechanical 
testing system (Texture Technologies, Corporation, Scarsdale, NY) was utilized 
to strain the specimens at a rate of 0.2mm/s until failure.  If the suture broke 
before pulling out of the tissue the test results were discarded.  The tensile 
strength at yield was calculated by dividing the maximum load, Fmax, by the 
original cross-sectional area, A, of the specimen.  The modulus of elasticity E, 
was determined from the slope of a line fit to the stress versus strain curve of 
each specimen.  
  
6.3.4 Implantation 
Female domestic swine (n=6) with a starting weight of approximately 120 
lbs were housed in accordance with the Guide for the Care and Use of 
Laboratory Animals under a protocol approved by the Institutional Animal Care 
and Use Committee.  24 hours before surgery animals were given 325 mg aspirin 
orally (PO).  Intramuscular (IM) telazol (4.4-6.6 mg/kg body weight), xylazine (2.2 
mg/kg) and atropine (0.05 mg/kg) were given as a preanesthetic.  2-4% 
Isoflurane was administered via nose cone until the animal was sedated enough 
to be safely intubated.  A surgical plane of anesthesia was maintained using 1-
3% isoflurane gas and a ventilator at 6-8 breaths/minute.  Prior to the incision 
animals were given ceftiofur (5 mg/kg IM).  An intravenous (IV) catheter was 
placed in the ear with an isotonic sodium chloride flow throughout surgery.  
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Heparin was given IV at an initial bolus of 10,000 U/kg followed by 5,000 u/kg 
every hour intra op when necessary.  Pancuronium (0.1 mg/kg IV) was given at 
the time of the incision.   
The aorta was reached through the fourth rib space via a left lateral 
thoracotomy.  The aorta was partially clamped and opened in the longitudinal 
direction.  Patch material was sutured over the defect using 6-0 prolene.   
Post operatively a 75 µg/hr fentanyl patch was placed on the dorsum for 
pain relief and carprofen (3mg/kg) subcutaneously (SQ) and buprenorphine 
(0.01-0.02 mg/kg) IM were given to bridge the gap until the fentanyl became 
effective.  Animals received 325 mg aspirin PO for 3 days post op and then 81 
mg/day PO until sacrifice.   
 
6.3.5 Gross Examination 
Each artery was photographed (Canon PowerShot A4000 IS) in vivo after 
the thorax of the animal had been re-opened.  The lumen was photographed 
after the artery was explanted.    
 
6.3.6 Histology 
All slides were prepared by IDEXX Bioresearch (Columbia, MO). Samples 
were fixed in 10% (v/v) buffered formalin, dehydrated with a graded ethanol 
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series, embedded in paraffin and cut to a thickness of 5 µm with a microtome.  
The histology slides were stained with hematoxylin and eosin (H&E), as well as 
van Gieson’s method to look at elastin and collagen was stained for using 
Masson’s trichrome.  All slides were viewed at 50x, 100x, 200x, and 400x on a 
Zeiss Axiophot (Carl Zeiss Microimaging, Inc., Thornwood, NY) and photographs 
were acquired using an Olympus DP70 (Olympus America Inc., Center Valley, 
PA) camera with DP Manager Version 1.21.107 as the acquisition software. 
 
6.3.7 Immunohistochemistry 
All slides were prepared by IDEXX Bioresearch (Columbia, MO).  Samples 
were fixed in 10% (v/v) buffered formalin, dehydrated with a graded ethanol 
series, embedded in paraffin and cut to a thickness of 5 µm with a microtome.  
The slides were deparaffinized using a standard protocol of xylene, to absolute 
alcohol, 95% alcohol to water.  They were then immersed in 5% bovine serum 
albumin (Sigma A3294-50) for 20 minutes followed by CD31 (Abcam ab28364) at 
a 1:50 ratio for one hour.  They were rinsed using a Dako wash buffer (Dako 
K1492).   Next the slides were submerged in the goat anti-rabbit IgG Alexafluor 
594 red (Invitrogen A11037) at a 1:500 ratio for 30 minutes followed by another 
Dako rinse and then put in bovine serum albumin for 20 minutes.  They were 
dyed with Actin Smooth Muscle (Dako M0851) at a 1:400 ratio for an hour, 
rinsed, and immersed in goat anti-mouse IgG Alexafluor 288 green (Molecular 
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Probes A11001).  Slides were rinsed again in Dako, then a coverslip with 
MoWiol(polyvinyl alcohol mounting medium with DABCO antifade - Fluka Cat 
#10981) was applied.  They were viewed on a Leica TCP SP8 MP Inverted 
spectral confocal microscope with tunable white light laser at the University of 
Missouri Cytology Core.   Images were taken using Leica software. 
 
6.3.8 Statistical Analysis 
GraphPad Prism v4.0 (GraphPad Software, Inc., San Diego, CA) was 
used to analyze experimental data. One-way analysis of variance (ANOVA) with 
significance set at p<0.05 was conducted followed by a Tukey-Kramer post-test 
to determine significant differences between means of the experimental groups 
for the mechanical testing and biocompatibility assays.  Values are reported and 
graphed as the mean ± standard error of the mean. 
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6.4 Results 
6.4.1 Suture Pullout Testing 
 The suture pullout testing showed that the bovine pericardial patch had a 
significantly higher Modulus of Elasticity and Tensile Stress at the maximum load 
when compared to any of the porcine tissue.  The values for each group can be 
found in Table 6.1 with the results graphed noting the significance in Figure 6.1.   
 
Table 6.1 Modulus of Elasticity (MPa) and Tensile Stress at Max (MPa) for each 
experimental group 
 Modulus of Elasticity 
(MPa) 
Tensile Stress at 
Max (MPa) 
Native 
Porcine 
3.28 ± 0.48 0.33 ± 0.05 
Decell 
Porcine 
3.63 ± 0.49 0.36 ± 0.06 
Crosslink 
Porcine 
3.99 ± 0.55 0.36 ± 0.04 
Bovine 
Pericaridum 
15.74 ±1.15 0.89 ± 0.05 
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Figure 6.1 Suture Pullout testing on porcine and bovine tissues.  The asterisk 
denotes a significantly higher value than the other experimental groups.  a) 
Modulus of Elasticity,  b) Tensile Stress at Max Load 
 
 
6.4.2 Implantation 
 Overall, implantation went smoothly for 5 of the 6 animals.  The sixth 
animal was awakening from the anesthetic when she experienced a cardiac 
event and could not be revived.  The thoracic cavity was reopened and the patch 
was still in place and not the cause of death.  All other animals survived to their 
time point of 6 months.  Figure 6.2 shows the approach, isolation, and 
implantation of the patch into the aorta.   
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Figure 6.2 Implantation of the material on the thoracic aorta 
a) Access to the thoracic aorta (black arrow) was done through the 5th and 6th rib 
space 
b) The aorta was isolated and partially clamped before a defect (black arrow) 
was made into the lumen 
c) The material in vivo just after implantation 
d) The material explanted less than 3 hours post implantation (non-survival 
animal)   
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6.4.3 Gross Examination 
 After 6 months the aortas were removed from the animals.  Upon 
approach minimal scar tissue was seen within the thoracic cavity of most of the 
animals (Figure 6.3).  The patch integrated smoothly on the luminal side with the 
native tissue. 
   
Figure 6.3 Thoracic aorta patched with the biomaterial after 6 months of 
implantation.   
 
a) The patch still in vivo.  The suture material can still be seen on the adventitial 
layer of the vessel.  There is minimal scar tissue such that the patch is visible 
through it. The arrows indicate the outline of the patch 
 
b) The lumen of the aorta with the patch.  There are no blood clots associated 
with the patch and grossly is has integrated smoothly with the host tissue.   
 
c) A cross sectional view of the aorta through the patch showing the smooth 
transition between patch and native tissue.   
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6.4.4 Histology 
 Figure 6.4a shows the patch before the decellularization process and the 
nuclei of the cells are clearly visible.  After decellularization the histology shows 
that the nuclear remnants have been removed (Figure 6.2 b-d).  The Masson’s 
trichrome staining and van Gieson’s staining highlight the elastin and collagen 
tissue present in the exctracellular matrix.  Figure 6.2e shows the presence of 
gold nanoparticles on the material before implantation.   
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Figure 6.4 Histology of native control tissue and pristine biomaterial 
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a) 100x H&E staining of native porcine aorta with cell nuclei present 
 
b) 100x H&E staining of decellularized aorta showing removal of cellular 
components 
 
c) 100x Masson’s trichrome staining of the biomaterial with a black arrow 
indicating collagen and the white arrow indicating lighter staining collagen 
 
d) 100x van Geison’s stain of the biomaterial showing the presence of the black 
elastin fibers.   
 
e) 1000x H&E staining of the biomaterial showing the presence of the AuNPs.   
 
f) 100x H&E staining of native tissue and the biomaterial at 6 months.  Arrow 
indicates the nuclei of cells that have moved into the patch area. 
 
g) 100x Masson’s trichrome staining of the biomaterial at 6 months with a black 
arrow the transition zone between the biomaterial and native tissue. 
 
h) 100x van Geison’s stain of the biomaterial at 6 monthsshowing the presence 
of the black elastin fibers.  The black arrow indicates that the area of biomaterial 
closest to the native tissue has characteristics more similar to the native tissue.   
 
  
 After six months the explanted patch material showed cellular integration, 
though there is still a difference between the biomaterial and the native tissue.  
Using H&E staining (Figure 6.5a) we can note that cells have infiltrated into the 
patch material.  There are no major congregations of immune cells, nor signs of 
infection or fibrosis around the patch.  The trichrome (Figure 6.5b) shows that the 
biomaterial has a higher amount of collagen when compared to the native tissue.  
There is red staining areas within the biomaterial though, indicating smooth 
muscle cell integration.  The van Gieson’s stain (Figure 6.5c) shows that the 
patch stains less for elastin than the native tissue.  The arrow in Figure 6.5c 
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points to a transition zone though, where it appears the biomaterial is becoming 
more similar to the native tissue.  
 
6.4.4 Immunohistochemistry 
 Immunohistochemical analysis showed that the cells present on the lumen 
side of the patches stained positively for CD31(red fluorescence labeled) which 
indicates endothelial cell regeneration (Figure 6.6b).  The vessel has repaired the 
area over the patch appropriately and is comparable to the control animal’s 
endothelial cell layer in Figure 6.6a.  The green fluorescence labeled SM actin 
stain showed that smooth muscle cells (SMCs) have re-populated the graft 
(Figure 6.6a, b).  Figure 6.6d is the patch just after implantation (non-survival 
animal) and highlights how much cellular integration occurred during the 6 
months.  In Figure 6.6a the native vessel is seen, and compared to Figure 6.6b 
which represents just the area associated with the patch.  Figure 6.6c shows the 
transition zone between the native tissue and the patch, highlighting that while 
there are still some differences in the way the smooth muscle cells are oriented, 
they are rebuilding within the extracellular matrix of the patch.   
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Figure 6.6 Immunohisotchemical staining of endothelial (red) and SMCs (green) 
taken at 200x. 
 
a)  Native aortic tissue taken from a control animal (no surgical intervention).  
There is a smooth line of endothelial cells present on the lumen of the vessel with 
typical SMC patterning below it. 
 
b) The nanocomposite biomaterial 6 months after implantation showing a 
smooth, single layer of endothelial cells (red) comparable to the control tissue.  
There are also SMCs present throughout the area below the endothelial cells.   
 
c) The white line indicates the transition between native tissue and the implanted 
biomaterial.  The SMCs have integrated the biomaterial and are forming patterns 
much like the native tissue.  There is a smooth layer of endothelial cells present 
on the luminal side.   
 
d) This image is of a patch that was implanted only briefly.  It shows a lack of 
SMCs or endothelial cell growth, indicating what is present in the other images is 
not autofluorescence, but evidence of true cellular integration and remodeling.   
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6.5 Discussion 
 A more intelligently engineered biomaterial could conquer the negative 
attributes associated with the currently available biologic and synthetic solutions.  
Previously extracellular matrices have been explored as a base material for 
wound healing [37].   Porcine arterial tissue has an extracellular matrix that 
allows for cellular in growth and wound healing.  In this study the decellularized 
arterial tissue was crosslinked and had AuNPs conjugated to it.  The material 
was studied mechanically compared to a commercially available biological patch.  
The biomaterial was then subjected to a long term in vivo study to determine how 
the native tissue would respond.   
 There were significant mechanical differences between the porcine aortic 
tissue when compared with the bovine pericardium.  The bovine pericardium 
showed a higher strength before failing, but was significantly stiffer than the 
porcine tissue.  In vivo the porcine tissue withstood the blood pressure of the 
thoracic aorta, so the strength at failing is not truly a concern.  Instead this data 
shows that the porcine aorta may mimic the native arterial tissue much better 
than the bovine pericardium does.  Wang et al. showed that more compliant graft 
may match mechanical and flow parameters better than a less compliant material 
[8].  As the suture pulls out more easily from the porcine tissue, surgeons may 
need to slightly change their methods to account for this.  However the porcine 
tissue may allow for better healing and a lower chance of thrombosis when 
compared to stiffer materials.   
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 The implantation process of this material went smoothly, with the 
exception of one animal lost to anesthetic complications and the aorta was still 
intact at death.  The surgeon did note that there was more hemorrhage around 
the suture bites in our material when he compared it to biomaterials he has 
previously implanted in humans.  While this is a concern, the bleeding was 
moderate and controlled quickly.  The initial physical attributes of the patch 
during surgery can be accounted for and given the integration and the wound 
healing response with the biomaterial; it is definitely worth making a change.  
After explantation the gross photos show that there was minimal scar tissue in 
the chest.  The animal did not try to wall it via the immune system as can be seen 
with some other materials. The gross view of the lumen shows a smooth, well 
integrated patch.  There were no thrombi seen as can occur when the body 
contacts a foreign material [38-40]. Typically the contact of blood will with an 
unknown material will lead to adhesion and aggregation of platelets and a 
coagulation response, which was not seen with this material [41].     
 The decellularized porcine aortic tissue showed that the native 
extracellular matrix remains after decellularization (Figure 6.4).  The collagen and 
elastin that are present in the biomaterial’s matrix can provide an organized 
scaffold for cells to adhere and proliferate onto [42].  The AuNPs that are present 
(Figure 6.4e) have been shown to increase stability, decrease inflammation, and 
slow down scaffold degradation [34, 43-46].  The lack of thrombosis and other 
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inflammatory and immune reactions may indicate that the biomaterial’s surface 
modifications are aiding in the healing process.   
 The histologic images show that while the biomaterial is integrated with 
native cells, there are still structural differences between the native vessel and 
the biomaterial.  The trichrome and van Geison’s stains show the biomaterial has 
less collagen and elastin still than the native tissue, but does have a zone where 
it appears to be remodeling into something more like the native tissue.  With the 
H&E staining we see minimal immune response and no signs of infection.  The 
body often responds to foreign materials with an inflammatory response including 
neutrophils, macrophages, and multi-nucleated giant cells [47].  This was not 
noted in our study.  Often when a vascular wall repairs itself there is a 
generalized thickening of the media due to over proliferation of smooth muscle 
cells known as intimal hyperplasia [48, 49].  On the histologic and gross images 
for this study there is no thickening of the intimal layer between the native tissue 
and the biomaterial.  Intimal hyperplasia is evident at six months if it is going to 
occur.  It was not seen in any of the animals here, another indicator of 
biocompatibility.   
 The results of the immunohistochemical staining were particularly 
promising.  They show definitive evidence that the vessel has appropriately 
begun to remodel into the biomaterial.  The CD31 stain highlighted the layer of 
endothelial cells that has covered the patch.  It is not overly thickened and 
comparable to the control tissue.  The presence of an endothelial cell layer is 
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important as decreases in endothelial derived substances result in a decreased 
ability to regulate coagulation [50].   When compared to the patch that had only 
been briefly implanted, the six months patches had excellent integration of 
smooth muscle cells in the extracellular matrix.  As previously discussed, smooth 
muscle cells can over proliferate during vascular repair.  However they must be 
present to properly rebuild the vessel as they also play a role in synthesizing 
extracellular matrix [51-54].   The immunohistochemical staining shows that they 
are infiltration the biomaterial in a pattern similar to the native tissue.  A longer 
term study might show total integration of the material.    
   
6.6 Conclusions 
 This long term study examines the potential of a novel nanocomposite 
biomaterial for vascular repair and blood contacting applications.  The biomaterial 
did not fail in any of the animals tested and the long term survival of five of the 
animals indicated the in vivo durability of the biomaterial.  It was able to withstand 
the pressure of the aorta while allowing for endothelial and smooth muscle cell 
re-growth.  The integration and healing seen during this study highlight the 
potential of this biomaterial to give the body a chance to correctly rebuild injured 
tissue.  The reaction of the body to the biomaterial supports our thesis that there 
would be minimal immune response, endothelial and smooth muscle cell 
regeneration, and overall excellent integration and biocompatibility.   Further 
studies should be done utilizing diseased animal models to see how the 
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biomaterial performs when attached to a more friable tissue in an environment 
that is not as capable of healing itself.  This nanocomposite biomaterial shows 
great promise as a vascular repair material.   
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Chapter 7 
FUTURE WORK 
 
7.1 Future Studies 
 Worldwide, people are three times more likely to die from cardiovascular 
disease than infectious and parasitic diseases combined [1].  Cardiovascular 
disease is a direct cause of mortality and morbidity, and improved treatments 
must be continually developed and refined [2-4].  The research presented in this 
dissertation demonstrates the viability of a novel nanomaterial tissue patch as a 
vascular repair device.  However, there are still questions about the long-term 
effects of the material and its components in vivo, as well as its effectiveness in 
diseased tissue.   
 In order to continue optimizing blood contacting materials, there needs to 
be further research into the molecular aspects of the interaction between the 
native cells and the biomaterial.  The first step in future work with this material is 
to perform more in vitro work regarding the reaction between the blood and the 
nanoparticle coated material.  Siminescu et al. showed that certain macrophage 
phenotypes play a role in the degradation of bioprosthetic heart valves 
crosslinked with glutaraldehyde, and McDade et al. demonstrated that the use of 
zero length crosslinkers like EDC allow for a better immune response [5, 6].  
Using these types of cell assays, future studies can determine the effects of 
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AuNPs on the immune response.  Cell migration studies can also be used to 
examine how AuNPs in conjunction with the base material affect different types 
of immune response cells and various cells associated with long-term wound 
healing.   
 All materials used in medicine must be completely explored.  Implanting a 
foreign material with nanoparticles leads to the question of how the nanoparticles 
will distribute or accumulate within the tissues.  It is highly likely they will stay in 
the immediate area of the biomaterial.  However, they might also be up taken by 
cells and enter the blood stream, and either be excreted or remain in the host 
tissue.  The biocompatibility of AuNPs has been discussed at length in the 
literature review of this dissertation, and this research did not see a loss of 
biocompatibility with the use of AuNPs.  A study performed by De Jong et al. 
demonstrated that 100 nm AuNPs were detected only in the blood, liver, and 
spleen 24 hours after being injected [7].  This indicates where the AuNPs from 
our biomaterial would go should they disassociate from the material.  Future 
studies should examine the lingering presence of the AuNPs at the implant site 
as well as the organ distribution and excretion route of 100 nm AuNPs.  The 
degradation of the base material- the porcine decellularized artery- should be 
studied along with the distribution of the AuNPs.  The ECM of the biomaterial 
should naturally degrade over time.  This could be studied using long-term 
studies and tagging the implant material.  Thein et al. showed that a green 
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fluorescent protein–collagen fusion could be used to tag ECMs [8].  This method 
could be used to tag our material before implantation in another in vivo study. 
 There are numerous arguments for further in vivo testing.  The studies 
contained here show that the material is feasible long-term in a healthy 
cardiovascular model.  An initial concern is that this is a porcine product being 
tested in swine.  Nonfunctional studies using the material as a xenograft in other 
species should be performed before it is used in humans.  Porcine tissue is 
currently used in human medical applications, so this is not a major concern.  A 
more pressing concern is that the material will be used in diseased individuals 
with vasculature more fragile than healthy swine.  In addition, these studies did 
not challenge the material with stresses such as increased blood pressure or a 
high fat diet.   
Swine are an excellent cardiovascular model for human medicine since 
they naturally develop atherosclerosis similar to humans.  Reitman et al. 
demonstrated that Yucatan pigs fed a high fat, high cholesterol diet for 10-12 
months had elevated serum cholesterol levels and developed accelerated 
atherosclerosis [9].  Other swine disease models include partial surgical ligation 
of the carotid arteries [10].  Our biomaterial could be implanted in one of these 
models to test its feasibility in diseased vessels.  Once implanted, the material 
could be further stressed by increasing blood pressure through exercise.  Emter 
et al. showed that swine can be trained to exercise on treadmills [11].  The use of 
exercise would stress the biomaterial and also allow studies to be performed 
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examining the effects of exercise and vascular remodeling.  The results of these 
studies will further bolster the biomaterial’s positive attributes.   
` The final aspect of future work to be performed is that of medical 
applications for this material.  In Chapters 5 and 6 we demonstrate the feasibility 
of this material in vivo, and its benign long-term response within the host.  These 
are all positive attributes of the material and should be considered not only for 
vascular repair, but for heart valve leaflets and cardiac wall repairs.  The blood 
compatibility of the material, as well as its integration abilities make it an 
excellent candidate for a wide variety of applications.   
 In conclusion, this dissertation has begun the extensive research needed 
to characterize, optimize, and discover the in vivo feasibility of a novel 
nanomaterial-tissue patch.  The research supports the conclusion that a 
biomaterial comprised of decellularized, crosslinked porcine arterial tissue 
conjugated with gold nanoparticles is biocompatible as well as blood compatible 
and can integrate into host vascular tissue with minimum of scar formation and 
other negative effects.  There is still much research that needs to be performed in 
order to understand how the material is interacting with the host tissue at a 
molecular level, as well as further in vivo studies to test it in diseased animal 
models.  The further development of this material has the potential to advance a 
state-of-the-art class of biomaterials.   
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